




















A thesis submitted in partial fulfilment for the requirements for the degree of               



















1. Concurrent registration for two or more academic awards 
  
 *I declare that while registered as a candidate for the research degree, I have not 
been a registered candidate or enrolled student for another award of the University 





2. Material submitted for another award 
 
 *I declare that no material contained in the thesis has been used in any other 











3.  Collaboration 
 
 Where a candidate’s research programme is part of a collaborative project, the thesis 
must indicate in addition clearly the candidate’s individual contribution and the extent 




4. Use of a Proof-reader 
 
 
 No proof-reading service was used in the compilation of this thesis. 
 
Signature of Candidate  ________ ____________________________________ 
 
Print name:   _______Mohit Arora________ 
 
Type of Award_________PhD___________ 
 












     Abstract       
Gliomas are primary brain tumours. Glioblastoma multiforme is a grade IV tumour 
and is the most aggressive type of tumour with a poor prognosis (overall survival 
approx. 12 months post diagnosis). Advances in diagnosis and treatment have been 
hindered by numerous factors including identification of novel target biomarkers and 
the ability of therapeutics to cross the blood brain barrier (BBB).  
Aptamers could advance the identification of novel drug targets because their 
properties allow them to act as both a targeting ligand and a drug delivery moiety. 
Aptamers are small and highly structured single-stranded oligonucleotides that bind 
with high affinity (within the low nano molar range) to a target molecule. Aptamers 
used in this study, SA43 and SA44 were generated by cell-SELEX and shortened, which 
showed selective binding to glioma cells. The target ligand was unknown.  
The aim of this project was to develop an aptamer precipitation or aptoprecipitation 
(AP) protocol to identify the target ligand of novel aptamers generated against 
different glioma cells. Commercially available glioma cell lines U87MG, 1321N1, and 
SVGP12 and short term patient derived cultures BTNW911, BTNW914, BTNW370, 
IN1528, IN1612, W2045 and W859 were first characterised using conventional 
staining methods. These cells were then assessed for binding with SA43 and SA44 
aptamers and 7 novel aptamers (TDM aptamers 2,3,7,9,10 and SAneg1 and SAneg2) 
using confocal microscopy and protein extraction methods. Confocal microscopy 
confirmed the binding of biotinylated aptamers to glioma cell lines and patient tissue 
derived short term cultures. Protein extraction from cells was optimised and AP of 
the targets was performed. LC-MS/MS analysis showed that 8 of the novel aptamers 
identified Ku70/80 heterodimer as the target in glioma cells. Ku70/80 was further 
confirmed as the target ligand for the aptamers by Western blot in glioma cells and 
siRNA knockdown in U87MG cells.  
This research will help in detecting new biomarkers for glioma and possibly other cell 
lines. It has helped in establishing a method for aptamer target detection. It can also 
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1.1 Brain Tumours 
Brain tumours are neoplasms in the brain which can arise either from the brain, termed 
as primary brain tumours or as ‘metastasis’ from other parts of the body (Ellenbogen, 
2012; Rotta et al., 2018). Like every neoplasm, primary brain tumours can be further 
divided into benign or malignant brain tumours (Ellenbogen, 2012; Greenberg, 2014). 
Benign brain tumours are tumours which do not recur or are very slow to recur. 
Malignant tumours are those which can recur at the primary site after treatment or can 
metastasise elsewhere (Bernstein and Woodard, 1995; Ellenbogen, 2012). Malignant 
brain tumours rarely metastasise outside the brain (Bernstein and Woodard, 1995; 
Mourad et al., 2005; Chang et al., 2018) (Figure 1.1).  
 
Figure 1.1 Diagram showing two broad types of brain tumours. 
 A) Glioma, primary tumour arising from glial tissue, B) Meningioma, tumour arising from 




Around 9000 new brain tumours are diagnosed in the UK every year (CRUK, 2011) and 
their incidence has grown to 11,432 in 2015 (CRUK, 2019). There was 50% incidence in 
males to females in 2011 (CRUK, 2011) and about 48% to 52% male to female ratio in 
2015. There is now greater incidence of primary brain tumour in the elderly population 
over 80 in the UK (CRUK, 2019), accounting for nearly a quarter of new cases every year. 
Astrocytoma (Park et al., 2019) remain to have the highest incidence in the group of 
primary brain tumours at 34% (CRUK, 2019) in both children and adults. This incidence 
is closely followed by meningiomas at 21% and other intracranial tumour incidence. The 
burden of metastasis to the brain is now greater than primary tumours (Jenkinson M, 
2017; CRUK, 2018) at about 16000 per year compared to 9000 new cases of primary 
brain tumours.  
1.2 Glioma 
The term ‘glioma’ is used to refer to all the tumours of glial origin. Gliomas have been 
historically classified according to the World Health organisation (WHO) from Grade I to 
IV (Louis et al., 2007) based on histopathological features. A newer classification system 
has come into practise since 2016 after review of molecular developments made in 
glioma diagnosis (Louis et al., 2016; Wesseling and Capper, 2018). Historically, prior to 
2016, Grade I and II tumours were classified as low grade tumours whereas Grade III and 
IV were considered as high grade. Patients with high grade tumours on histopathological 
diagnosis have had the poorest survival prognosis. The prognosis is still poor but 
molecular diagnosis has helped to further diversify the tumour types and provide 
appropriate treatment modality. 
Addressing the previously known classification of gliomas first, Glioblastoma Multiforme 
or GBM is the most malignant brain tumour of glial origin (Holland, 2000; Behin et al., 
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2003). It refers to grade IV glioma and is classified due to the appearance of histological 
characteristics of vascular proliferation, mitoses, pleomorphism and central necrosis 
(Louis et al., 2007; Agnihotri et al., 2013; Greenberg, 2014). Glioblastoma multiforme is 
now a historical term since the advent of the 2016 WHO classification of brain tumours 
(Louis et al., 2016). Glial brain tumours arise from a common progenitor and 
subsequently differentiate to give rise to various grade of glioma (Huse and Holland, 
2010; Agnihotri et al., 2013) (Figure 1.2). They may develop de novo (primary 
glioblastoma) or by progression from low grade glioma (Ohgaki and Kleihues, 2007; 
Bready and Placantonakis, 2019). 
 
Figure 1.2 Flow diagram showing the origin of various glial tumours, taken from 




1.2.1 Current outcomes in glioma and targeted therapy 
Patients diagnosed with grade IV glioma have an overall poor prognosis (Sanai and 
Berger, 2008). Based on the extent of initial resection of tumour, the prognosis is better 
with concurrent chemotherapy and radiotherapy. Studies have shown increase in the 
survival rates of patients with grade IV glioma to a median of 12 months (Krex et al., 
2007). Recent advances have improved median survival upto 21 months (Fabian et al., 
2019b). Around 4,300 benign cancers of the brain (McKinney, 2004) are also diagnosed 
every year, making brain cancer the 16th commonest cancer in the UK. Seven people out 
of a 100,000 will have a newly diagnosed Brain tumour UK (McKinney, 2004). Glioma 
accounts for two percent of newly diagnosed cancers in adults in  the population in the 
UK every year (McKinney, 2004). 
Despite the advances in treatment of other cancers, treatment for brain tumours is still 
far from providing cure. Improved outcomes in primary cancers of the breast, lung, 
melanoma and renal are a testament to the advances in treatment and awareness of 
these tumours.  
Brain tumour treatment is also hampered by the bioavailability of the drugs across the 
blood brain barrier (Deeken and Löscher, 2007). Tight junctions in the brain along with 
adherens proteins prevent paracellular diffusion (Warren, 2018), thus affecting the 
bioavailability of systemically administered drugs. This remains controversial for 
treatment of metastasis and high grade tumour where blood brain barrier is disrupted. 
Tumour enhancement in metastasis is also due to blood brain barrier disruption (Fortin, 
2012). Grade IV gliomas do alter blood brain barrier but it is sufficiently intact to prevent 
drug distribution to the tumour cells (Da Ros et al., 2018). 
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There also remains the need to be selective in targeting tumour cells as it is difficult to 
recognise the true margins of the primary brain tumour. Recent advances in glioma 
surgery have been helped with 5-aminolevulinic acid (5-ALA) use (Stummer et al., 2008; 
Stummer et al., 2011; Hadjipanayis et al., 2015) including surgery for other brain 
tumours as hemangioblastoma (Utsuki et al., 2011). Current treatment plans for brain 
tumours are based on surgical debulking, concurrent chemotherapy and radiotherapy 
(NICE.org.uk, 2018). 
Recent advance in targeting cell growth has resulted in reduction of cell mitosis and 
reducing the growth of grade IV glioma by application of magnetic field (Omar, 2014; 
Fabian et al., 2019a; Korshoej et al., 2019). Tumour treating fields (TTF) are low intensity 
and intermediate frequency electric field that disrupts cell division and hence reducing 
tumour growth (Hottinger et al., 2016). This has resulted in improved median 
progression free survival with TMZ to 20 months from 16 months with TMZ and DXT 
alone (Hottinger et al., 2016) in grade IV glioma. Despite a break through, the treatment 
is not mainstream due to the high cost of the equipment needed for treatment. It is not 
approved by NICE since it does not meet the QALY (Quality adjusted life years) threshold 







1.2.2 World Health Organisation (WHO) Classification of glioma 2007 
The WHO 2007 system of classification of glioma  was based on the morphology of tissue 
and immunohistochemical features of the tumour sample (Louis et al., 2007). The first 
WHO classification of brain tumours was defined by Zulch in 1979 (Zulch and Mennel, 
1977; Zulch, 1980, 1981). This was based on Rudolf Virchow’s first reported brain 
tumour classification from 1863 and was based on tissue and cell morphology. Features 
such as mitosis, hyper cellularity, microvascular proliferation and necrosis were 
included. The newer WHO 2016 classification supersedes and adds molecular staining 
with IDH, ATRX, MGMT and 1p/19q co-deletion for further classification to the earlier 
WHO 2007 morphological diagnosis of glioma.  
Due to the use short term cultures in this project from patient biopsies was based on 
the 2007 WHO classification of gliomas, this section is integral to the presentation of the 
results. Historically, based on the morphological characteristics, the primary brain 
tumour can be divided into multiple grades (Table 1.1 and Table 1.2). The classification 
takes into account the cell lineage and proliferation with presence of mitosis and 
proliferation markers used in standard immunohistochemistry techniques(Louis et al., 
2007). Presence of two types of cell in the tumour gave the terms “oligoastrocytic” 
tumours which is now not used as per the recent WHO 2016 classification(Louis et al., 







Table 1-1 Types of neuroepithelial tumours 
 Classification Tumour  
1 Astrocytic tumours Infiltrating astrocytoma 
Pilocytic astrcytoma 
Pleomorphic xanthoastrocytoma 
Subependymal giant cell astrocytoma 
2 Oligodendroglial tumours Oligodendroglioma 
3 Ependymal tumours Ependymoma 
4 Mixed glioma Oligoastrocytoma 
5 Choroid plexus tumours Papilloma 




Dysembryonic neuroepithelial tumour 
(DNET) 
7 Pineal tumours Pineocytoma 
Pineoblastoma 
8 Embryonal tumours Neuroblastoma 
Retinoblastoma 









Table 1-2  Histological classification of diffuse gliomas and their median survival (Louis 
et al., 2007) 
Cell lineage WHO 
grading 
Histological subtype % 
Incidence 
Astrocytic tumours Grade I Pilocytic astrocytoma 5-6% 
 Subependymal giant cell 
astrocytoma 
<1 
Grade II Diffuse astrocytoma, pleomorphic 
astrocytoma 
10-15% 
Grade III Anaplastic astrocytoma 10-15% 





Grade II Oligodendroglioma 2.5% 
Grade III Anaplastic oligodendroglioma 1.2% 
Oligoastrocytic 
tumours 
Grade II Oligoastrocytoma 1.8% 




1.2.3 Pilocytic Astrocytoma  
Pilocytic Astrocytoma (PA) is a slow growing, WHO grade I astrocytoma, most commonly 
affecting patients in the second decade of life (Ellenbogen, 2012). They can differ 
histologically from diffuse to fibrillary astrocytoma (a tumour matrix rich with neuroglial 
fibrils which give the tumour its name and firm consistency). They have a benign course 
due to lack of invasion and malignant tendency. PA are usually resectable and rarely 
recur or undergo malignant transformation (Ellenbogen, 2012; Nelson et al., 2019). 
Primary surgical debulking with chemotherapy is effective in children with pilocytic 
astrocytoma (Goodden et al., 2014) and good resection predicts reduced risk of 
progression (Nelson et al., 2019). 
1.2.4 Astrocytoma 
The 2007 WHO classification describes astrocytoma as Grade II, ‘low grade’ tumours 
(Louis et al., 2007). These usually occur in the fifth decade of life, with a median age of 
35 years (Whittle, 2004)and account for around 15-25 % of gliomas in most series of 
cases published (Ellenbogen, 2012; Lanese et al., 2018). Astrocytoma are slow growing 
and the usual presentation is with a seizure (Whittle, 2004). Magnetic resonance 
imaging or MRI is the gold standard for non-invasive imaging for low grade gliomas 
(Ellenbogen, 2012). Pathologically, they are less cellular show no calcification and have 
no mitoses (Ellenbogen, 2012; Forst et al., 2014) (Figure 1.3). Treatment remains surgical 
resection, with 80 % 5 year survival rate for gross resection, 50 % for partial resection 
and 45 % for biopsies (Ellenbogen, 2012). EORTC or European organisation for research 
and treatment of cancer have conducted trials for low grade tumours, EORTC 22844 and 
EORC 22845 (Forst et al., 2014). They identified poor prognostic indicators relating to 
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tumour size greater than 6 cm, age over 40 at presentation, midline shift and presence 
of neurologic deficit at diagnosis. 
 
Figure 1.3  A micrograph showing astrocytoma, taken from Holland, 2010  (Huse and 
Holland, 2010). 
1.2.5 Anaplastic Astrocytoma  
Anaplastic astrocytoma (AA) is usually seen from the second to the fifth decade of life 
and AA can be either malignant transformation or as primary presentation (Ellenbogen, 
2012; Forst et al., 2014). WHO 2007 classifies them as grade III tumours and they 
represent 10-15% of gliomas (Ellenbogen, 2012). Patients can present with various 
symptoms like seizures, confusion, headache and focal neurological deficits and 
sometimes being completely asymptomatic. They show contrast enhancement on CT 
scans and also have mass effect and oedema (Ellenbogen, 2012). MRI imaging is also 
likely to show heterogenous enhancement. Pathologically, AA show mitotic activity, 
increased cellularity and anaplasia (Figure 1.4). Treatment comprises of surgical 
resection followed by radiotherapy (Ellenbogen, 2012). Recent recommendation from 
NICE advice on 4-6 cycles of PCV concomitant with radiotherapy. After completion, a 
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further 12 cycles of temozolamide is recommended to patients with IDH wildtype, 
without 19/19q codeletion (NICE, 2019). 
 
Figure 1.4 A micrograph showing anaplastic astrocytoma, taken from Holland, 2010  
(Huse and Holland, 2010). 
1.2.6 Glioblastoma multiforme  
Glioblastoma multiforme or GBM is the most malignant brain tumour of glial origin 
(Behin et al., 2003) (Figure 1.5).  
 




The term ‘glioblastoma’ was defined by Virchow (1863) as a tumour of glial origin. In 
1926, Bailey and Cushing (1926) used the name ‘Glioblastoma Multiforme’ for the first 
time due to the variate, polymorphic features of the tumour on histology. As the term 
‘multiforme or polymorphic’ implies, the most salient feature is the diversity of tissue 
patterns and cell forms encountered including anaplastic astrocytes, gemistocytic, 
fibrillary or pilocytic areas; and the presence of astroblastic, oligodendroglial, and 
dedifferentiated cells. Río Hortega (1932) and Polak (1966) described the 'isomorphic 
glioblastoma’ as a tumour constitute of little round glial cells which is distinct from a 
glioblastoma multiforme (Ellenbogen, 2012) (Figure 1.6).  
 
Figure 1.6 A micrograph showing Glioblastoma multiforme, taken from Holland, 2010 
(Huse and Holland, 2010). 
Patients usually present with headaches, personality changes and focal deficits and 
usually are very progressive in symptoms. GBM are the most frequent and aggressive 
primary brain tumours found in adults (Holland, 2000) arising from the glia, which is the 
precursor of the central nervous system. Glia or glial cells are supportive cells in the 
nervous system (Purves D, 2001.).They are supportive cells which help in the function of 
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neurones and outnumber them 3 to 1 (Purves D, 2001.). GBM occur mostly in either the 
sixth or the seventh decade of life but increasing incidence is being seen earlier in life. 
GBMs account for around 5000 new cases of brain cancer (malignant) diagnosed every 
year in the UK (McKinney, 2004).  
GBM is the most common primary, intra-parenchymal, brain tumour and accounts for 
30% of brain tumours and 50% in series representation (of documented cases) 
(Ellenbogen, 2012). GBM are characterised by heterogeneous enhancement on CT and 
MRI imaging (Ellenbogen, 2012).  
1.3 WHO 2016 classification of glioma 
Since the last revision in 2007 of the WHO grading system, a need for further 
stratification was needed due to molecular advancement techniques. The WHO 2016 
classification takes into account molecular developments in glioma, but also creates 
room to grade without the molecular results, to allow diagnosis in regions where such 
tests are either inaccessible (Banan and Hartmann, 2017; Wesseling and Capper, 2018). 
A layered system of reporting was replicated from haematological reporting (Banan and 
Hartmann, 2017), incorporating molecular results. A three layered approach to results 
was adapted, with the top layer being the ‘integrated results of lower layers’ (Banan and 
Hartmann, 2017). Layer 2 is the histological diagnosis, layer 3 the grading and a layer 4 
of molecular characteristics (Banan and Hartmann, 2017). 
An important component in layer 4 is the application of two rules. Firstly, molecular 
results beats histology, as that is likely to define change in management. Secondly, the 
term ‘not otherwise specified’ or NOS was added in layer 4 for geographic regions where 
molecular testing is not available or the tissue sample is degraded and untestable (Banan 
20 
 
and Hartmann, 2017). IDH (isocitrate dehydrogenase), ATRX (alpha-thalassemia/mental 
retardation) and TERT (telomerase reverse transcriptase) are tested and help to 
diagnose tumour samples (Banan and Hartmann, 2017). It has also helped to remove 
the terms glioblastoma with oligodendroglial features and oligoastrocytomas  from 
diagnosis with the help of 1p/19q deletion diagnosis being incorporated (Banan and 
Hartmann, 2017).  
1.4 Current Treatment modalities for Glioma  
Histological diagnosis is of paramount importance prior to further treatment in glioma 
(Ellenbogen, 2012) and confirmation with molecular state (Banan and Hartmann, 2017). 
The molecular analysis since WHO 2016 adds to the diagnosis and aids in directing 
treatment. Surgery, followed by radiotherapy and chemotherapy though still remains 
the mainstay of treatment for GBM. Radiotherapy and chemotherapy can be used 
together or individually as suited to the patient’s tumour. Surgery is usually followed by 
concomitant radio-chemotherapy for six weeks with temozolamide (Stupp et al., 2005; 
Greenberg, 2014; NICE, 2019). Further, adjuvant chemotherapy is given for six months 
and continued longer depending on radiological stability and the patient’s general 
condition. Due to the aggressive nature of the tumour, the median survival rate is 
around fourteen months. Two year survival is 27 % and five year survival rate is 5 % 
(Ellenbogen, 2012; Hottinger et al., 2016).  
1.4.1 Surgical excision of glioma  
Primary brain tumours still remain incurable and the aim of the treatment lies in 
alleviating the symptoms and prolongation of meaningful life. Surgery helps in reducing 
the tumour size and bulk (Figure 1.7). Surgery also provides the vital histological 
diagnosis for further treatment by chemo-radiotherapy and can act as an access for 
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delivery of local chemotherapy where needed (Rampling et al., 2004). Maximal, safe 
tumour resection followed by concomitant chemo-radiotherapy is the guidance as 
provided by NICE (NICE, 2019).  
 
Figure 1.7 Diagram showing craniotomy for excision of tumour, taken from neuros.net 
(Neuros.net, 2014) 
1.4.2 Tumour debulking and in situ chemotherapy  
It is already known that maximal excision of tumour results in better outcome for the 
patient (Hentschel and Sawaya, 2003; Stummer et al., 2008; Stummer et al., 2011; 
Duffau, 2018). Adequate and safe tumour excision has been shown to reduce the 
morbidity involved with such surgeries and the mortality. The extent of tumour excision 
depends on the eloquence of the brain region it involves. Advances in imaging 
techniques like functional magnetic resonance imaging (fMRI) and surgery using brain 




Based on the histological diagnosis, in situ chemotherapy can be instituted at the time 
of surgery. This has been shown to be beneficial as the direct delivery of the 
chemotherapy is within the blood brain barrier, an area of “constant barricade” of 
systemic chemotherapy agents. ‘Carmustine’ wafer chemotherapy when given to grade 
IV glioma patients results in statistically significant improvement in meaningful survival 
(Stupp et al., 2005; McGirt et al., 2009) (Figure 1.8). 
 
Figure 1.8 Kaplan-Meier survival plots after primary resection of GBM and 
fractionated radiotherapy in patients ≤ 70 years old.  
Patients receiving concomitant TMZ according to the Stupp protocol in addition to 
Gliadel wafer implantation (30 patients) demonstrated improved survival compared with 
patients receiving Gliadel wafers and XRT alone (78 patients); median survival, 21.3 
versus 12.4 months, respectively (p = 0.005) (McGirt et al., 2009). 
Carmustine wafers have to be used only in cases of 90 % resection and only within 
specialized centers (NICE.org.uk, 2018). Their use is said to affect overall survival but 
there is increased incidence of surgical site infection as an adverse event (Chowdhary et 




Figure 1.9 Kaplan-Meier curve of overall survival in patients receiving 
radiotherapy alone versus radiotherapy and temozolamide (Stupp et al., 2005).    
NICE guidance on grade IV glioma management is based on the Stupp protocol for six 
weeks of concomitant chemotherapy and radiotherapy with temozolamide followed by 
12 months of adjuvant temozolamide (Stupp et al., 2005; NICE, 2019). The above survival 
graph (Stupp et al., 2005) shows the increased survival with temozolamide and 
radiotherapy together. 
1.5 Grade IV glioma and recent trials 
Glioblastoma Multiforme, now a historical term as per the WHO 2016 classification 
(Louis et al., 2016), still rings the death knell for the patient. Since the Stupp protocol 
(Stupp et al., 2005) in 2005, multiple drug trials and therapies have been researched in 
grade IV glioma with varying success. Carmustine wafers or gliadel (Westphal et al., 
2003) have been used for grade four glioma and is approved to be used by NICE in select 
patients who meet the criteria (McGirt et al., 2009; NICE, 2019). Overall adaptation 
varies and it does come with its own set of risks and complications (McGirt et al., 2009). 
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Antiangiogenic drugs have been researched for use in glioma (Lombardi et al., 2017), 
since grade IV glioma have neovascularization and over expression of VEGF (Vascular 
endothelial growth factor). Cilengitide is one of the anti-angiogenic agents used which 
is an integrin receptor inhibitor. Integrins are widely expressed in grade IV glioma and 
help in tumour migration (Lombardi et al., 2017). Cilengitide only showed a modest 
benefit in OS (Nabors et al., 2015) and ended after phase 2 study. Avastin or 
bevacizumab did not show any benefit in primary grade IV glioma (Iwamoto and Fine, 
2010). Bevacizumab is an anti-VEGF antibody and the rationale for use was due to the 
overexpression of VEGF in glioma. It has shown some benefit in recurrent grade IV 
glioma (Wenger et al., 2017) with PFS of 5.4 months in responders compared to 1.9 
months in non-responders. It is not currently approved by NICE for recurrent grade IV 
glioma (NICE, 2019). 
REGOMA (regorafenib in relapsed glioma) is a trial which has looked at use of 
regorafenib in relapsed grade IV glioma after the Stupp trial (Lombardi et al., 2018). 
Regorafinib is an oral multi-kinase inhibitor which targets angiogenic and oncogenic 
receptor tyrosine kinase (Krishnamoorthy et al., 2015). It has concluded its phase 2 with 
improved OS (overall survival) and PFS and a phase 3 trial is being planned. Checkmate 
143 is a trial which has looked at the use of Nivolumab, an anti-programmed cell death-
1 antibody (Filley et al., 2017). Nivolumab has shown promise in other cancers (Guo et 
al., 2017) but it has not shown a prolongation in the OS in recurrent grade IV glioma 
patients. Further research is likely to continue as  a small subgroup of 8% patients did 
show a favourable response (Filley et al., 2017).  
PARADIGM 2 (Olapraib and radiotherapy for people with glioblastoma trial) (Fulton et 
al., 2017) is an ongoing study looking at targeting PARP (Poly ADP-ribose polymerase) 
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which is overexpressed in cell repair and in other cancers such as breast and peritoneal 
cancer. It is an ongoing research and does hold promise for future therapies (Morales et 
al., 2014). Novo TTF (Omar, 2014; Hottinger et al., 2016; Benson, 2018) which uses the 
application of magnetic fields to the dividing tumour cells to arrest growth has shown 
promise of increased OS to 20 months. 
Despite the widespread research, progress in improving survival in grade IV glioma is 
slow. There lies a role in genetic targeting and using bio-active agents, which are 
directed at molecular targets in the cell (Chamberlain, 2011). Recent advances in the last 
decade since WHO 2007 to the WHO 2016 classification of glioma, molecular advances 
have been recognised and therapy is modulated according to known IDH, ATRX and 
MGMT status (Louis et al., 2016; NICE, 2019). 
 Tumour specific antibody targeting has been suggested in the literature towards brain 
tumours (Sampson et al., 2000). There is a shift from systemic to site specific tumour 
therapy using targeted interleukin-2 (Schrama, 2004) and antibody-directed enzyme 
prodrug therapy or ADEPT (Sharma et al., 2005). Antibodies were initially termed as the 
‘magic bullet’ for targeted cancer therapy (Chester, 2004) in the early 1990s. Further 
developments in technology have brought antibodies for clinical applications, with 
predicted effects in animal models and cancer patients (Chester, 2004). There still 
remains a fundamental challenge in differentiating between normal and abnormal cells 
in cancer biology (Phillips et al., 2008) when using antibodies. Systematic Evolution of 
Ligands through Exponential enrichment or SELEX (Ellington and Szostak, 1990) is a 
technique specifically suited to developing biomarker probes (Stoltenburg et al., 2007; 
Phillips et al., 2008). The products of SELEX are termed as aptamer (Ellington and 
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Szostak, 1990; Tuerk and Gold, 1990). Aptamers have been researched on in grade IV 
glioma and may help some future treatments towards glioma (Cerchia et al., 2002) 
1.6 Aptamers  
Aptamers are small, single-stranded oligonucleotides, which contort to form various two 
dimensional structures and tertiary three dimensional structures due to hydrogen 
bonding (Tuerk and Gold, 1990) (Figure 1.9). 
 
Figure 1.10 Diagram showing an aptamer molecule nestled on its target (Srisawat, 
2014) 
They bind with high affinity (within the low nano molar range) to a target molecule by 
providing a limited number of specific contact points embedded in a larger, defined 
three-dimensional structure (Mayer, 2009). Aptamer discovery is attributed to findings 
of virus associated RNA (VA RNA) during studies on human immunodeficiency virus (HIV) 
(Cullen and Greene, 1989; Marciniak et al., 1990). Further studies led to the significance 
of this functionalised RNA to be used as a therapy and coined the term 
‘aptamer’(Ellington and Szostak, 1990; Tuerk and Gold, 1990), ‘aptus’ – to fit and ‘meros’ 
– part. Production of aptamers using SELEX (Systemic Evolution of Ligands by 
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Exponential enrichment) could generate highly specific aptamers to the target molecule. 
The two groups produced similar conclusions but with different approaches. Tuerk and 
Gold (1990) targeted a molecule with known functionalised RNA interaction while 
Ellington and Szoztak (1990) produced novel functionalised RNA towards new targets. 
Hence, by exposing targets to a random library of DNA and RNA sequences, high affinity 
structures could be obtained with diagnostic and pharmaceutical value was proved. 
1.6.1 Aptamers as drug targeting agents 
Traditional SELEX works by a positive selection towards a known target and a negative 
selection against a non-target (Yan and Levy, 2009) (figure 1.10).  
 
Figure 1.11 SELEX – Systematic Evolution of Ligands by exponential enrichment 
Image describing the process of SELEX, the starting point being the reaction of aptamer 
library with the targets. Positive aptamer sequences are then reacted with negative 
controls to remove common binding targets and then PCR the left over aptamers, thus 
generating aptamers positive to the target and negative to the control. 
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SELEX can be modified by doing a negative selection against an unwanted target (Cerchia 
et al., 2005; Pestourie et al., 2006). Negative selection especially helps when positive 
selection is done against an unknown target but an undesirable target is used for 
negative selection. (Sampson, 2003). 10-15 cycles of SELEX is likely to deliver  an aptamer 
with high affinity and specificity to its target (Shigdar, 2010). 
Aptamers have been shown to distinguish between protein kinase C (PKC) isozymes 
which are 96% identical (Osborne et al., 1997). The final binding of an aptamer is highly 
specific due to its conformational tertiary and quaternary (Baird and Ferre-D'Amare, 
2013) state it contorts into (Cerchia et al., 2009; Cibiel et al., 2012).  The final tertiary or 
quaternary structure of the aptamer binds due to hydrogen bonds, Van der Waals forces 
and base pairing (Shigdar, 2010) (figure 1.11).  
A disadvantage of the SELEX process is the uncertainty of success of the process (Mayer, 
2009). Proteins which are positively charged under physiological conditions are excellent 
target and are ‘aptamerogenic’ (Mayer, 2009). 
 
Figure 1.12 Secondary and tertiary structure of aptamer 
a) Secondary structure of aptamer with straight components with base pairing and 
‘hair pin’ ‘free’ ends available for binding. b) The tertiary structure of aptamer with 
free ends available for binding to targets (Klussman, 2005). The tertiary structure is 
formed by various binding forces and determines the final target binding.  
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1.6.2 Review of current aptamers for therapy 
Aptamers (Ellington and Szostak, 1990; Tuerk and Gold, 1990)  have been compared to 
antibodies (Jayasena, 1999) and projected as the future for diagnosis and treatment as 
a replacement for antibodies. In vitro SELEX can generate aptamer towards nearly most 
targets (Schüling et al., 2018). Applications of aptamers as therapeutics depends on their 
affinity to the target molecule (Brody and Gold, 2000). This has been demonstrated from 
NX1838, an aptamer towards the 165 isoform of vascular endothelial growth factor or 
VEGF (Ruckman et al., 1998; Brody and Gold, 2000). VEGF is implicated in pathological 
growth of blood vessels in proliferative conditions like age-related macular 
degeneration. Pegaptanib or ‘macugen’ is the first anti-VEGF aptamer approved by the 
United States Food and Drug Administration (USFDA) for use as intra-ocular injection for 
combating age related macular degeneration in 2005 (Ng et al., 2006). It is administered 
via an intra-ocular injection and has US FDA approval since 2005 (Bouchard et al., 2010). 
VEGF resistant molecules have been described to be effective for controlling 
angiogenesis in highly vascular tumours like glioblastoma. The PDGF-B blockade DNA 
aptamer, AX102, leads to the reduction of pericytes in Lewis Lung Carcinoma (Sennino, 
2010; Takano, 2012). These are evidences of current aptamer research and the potential 
of using aptamers for further applications in therapy.  
Similar to antibodies, aptamers can also be used as diagnostic agents (Brody and Gold, 
2000) and for analytic applications (Tombelli et al., 2005; Tombelli et al., 2007). They can 
be used as target validation tools (Blank and Blind, 2005) and as sensors for platelet-
derived growth factor (PDGF) which is an important protein regulating cell growth and 
division (Degefa and Kwak, 2008). 
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Aptamers have also been used as fluorescent beacon for measuring water hardness 
(Lerga and O'Sullivan, 2008), an electrochemical sensor for detecting adenosine (Feng 
et al., 2008; Chakraborty et al., 2009; Wang et al., 2009) using methylene blue as the 
indicator. Surface enhanced Raman scattering (SERS) has been demonstrated to detect 
adenosine (Chen et al., 2008) using aptamer signalling, thus demonstrating a method 
for adenosine assay. Adenosine is an important substrate in biological reactions 
(Huizenga and Szostak, 1995) and it is also a powerful vasodilator of blood vessels and  
a biological cofactor. Aptamers for coronary artery disease (NU172), von Willebrand’s 
disease (ARC1779), haemophilia (ARC19499) and diabetes mellitus (NOX-E36) are 
currently in clinical trials (Gold et al., 2012; Sundaram et al., 2013). NOX-E36 trial 
concluded in 2014 and showed safety and efficacy of aptamer drug delivery by 
intravenous and subcuticular routes for patients with diabetes mellitus type 2 and 
albuminuria. The drug showed disease modifying characteristics by improving albumin 
to creatine ratio and also reducing glycated haemoglobin (HbA1c) in blood (NOXXON, 
2015). The ARC19499 aptamer study showed correction in bleeding times and thrombin 
generation in phase 1 but was terminated due to inconsistency of results (Hartmann and 
Croteau, 2016). 
Aptamers have been conjugated with nanomaterials (Yang et al., 2011) like gold, silica 
and carbon nanotubes for a variety of applications. Gold nano particles conjugated with 
aptamers have been used as sensing platform for thrombin (Li et al., 2008) which is an 
important component for thrombosis and haemostasis (Bock et al., 1992). Metal 
nanotubes, using gold and silver, were utilised for detection of vasopressin using 
aptamer-based assay and SERS (Huh and Erickson, 2010). Similar detection was 
performed for mercuric ion Hg₂⁺ using silver nano particles (Wang and Chen, 2009). 
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Aptamers have been shown to work as molecular probes to detect cancer (Phillips et al., 
2008) and in some cases to inhibit biological function of such molecule (Cerchia et al., 
2002) as PDGF-B. Aptamers in central nervous system (Yang et al., 2007) have been used 
by developing against prions of transmissible spongiform encephalopathy (Weiss et al., 
1997). This can help in developing diagnostic application towards transmissible 
spongiform encephalopathy diagnosis. Tenascin-C is a molecule overexpressed in  
wound healing and tumour growth (Yang et al., 2007). Anti-Tenascin-C aptamers have 
been isolated towards tenascin-C expressing glioblastoma cells (Hicke et al., 2001; Hicke 
et al., 2006) and can be used for tumour targeting, for delivery of chemical agents or 
radioisotopes. 
Importantly, aptamers are not problematic with bacterial or viral contamination 
(Schüling et al., 2018). Despite bacterial or viral contamination, they can still be used in 
the lab. Though if the final use is therapeutic, that might not be the case. They can be 
stored at room temperature in an non-constituted state (Yan and Levy, 2009; Bunka et 
al., 2010).They are also a lot less expensive than antibodies (Yan and Levy, 2009). They 
can easily be produced and more economical to produce (Jayasena, 1999). The aptamer 
sequence can be emailed to anyone in the world and can be locally produced by the 
manufacturer. They are much smaller in size and is non-immunogenic due to being DNA 
or RNA only. 
1.6.3 Disadvantages of aptamers and likely solutions 
RNA and DNA are present in all living forms and are unstable in serum. Chemical 
modification can though make them more stable and resistant to enzymes (Osborne et 
al., 1997). The stability of modified anti-bFGF (basic fibroblast growth factor) aptamer 
was increased 1000 fold compared to anti-VEGF (vascular endothelial growth factor) 
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aptamer by addition of pyrimidines (Jellinek et al., 1995). Hence it is likely that aptamers 
will be confined to intra-venous administration in near future and not for oral 
consumption. Disulphide bonds in secondary structure provides thermal stability to the 
aptamer (Osborne et al., 1996; Lu et al., 2008). Phosphorothioate linkages to the 5’ and 
3’ end provides stabilisation against exonuclease degradation (Green et al., 1995). 
Aptamers are also prone to nuclease degradation when compared to antibodies 
(Schüling et al., 2018). 
1.6.4 Review of Current Aptamers in Glioma 
In-vitro experiments performed by certain researchers have laid claim to certain DNA 
and RNA sequences of aptamers to be glial specific (Cerchia et al., 2009). The aim of the 
research was to generate tumour specific aptamers using SELEX against glioma cell lines. 
They performed initial 14 rounds of SELEX against U87MG cell line after which they came 
up with 71 aptamer sequences which could be categorised under 10 families. Further 
screening isolated the number to eight sequences which are thought to be glial specific 
and tested against other cancer cell lines and mouse fibroblasts. A-172 glioblastoma cell 
line has also been used to find glioma specific aptamers and their affinity tested using 
flow cytometry and binding analysis (Bayrac et al., 2011). TTA1, an aptamer to the 
extracellular matrix protein tenascin-C has been found to be taken up by breast, glioma, 
lung and colon tumours and it shows potential to be used as targeted chemotherapy 
(Hicke et al., 2006). Techniques for targeting tumour cells with aptamers have been 




1.6.5 Future directions for glioma targeting aptamers 
Techniques for cancer cell detection have recently been described using aptamers which 
would improve control over diagnosis and therapeutics (Pu et al., 2010). ChiP or 
chromatin immunoprecipitation is a technique which describes its use as a tool for 
studying transcription factor binding. ChIP can help in isolating the cellular structures 
responsible for binding of the aptamers (Spencer et al., 2003); (Viens et al., 2004). The 
technique combines chromatin immunoprecipitation and DNA microarray analysis to 
identify protein-DNA interactions that occur in living cells. Protein-DNA interactions are 
captured in vitro by chemical crosslinking (Aparicio et al., 2004), followed by cell lysis 
and immunoaffinity purification of the desired protein. Immnoaffinity purification will 
co-purify DNA fragments that are associated with the protein (Lee et al., 2006) and help 
in identification of relevant targets. Micro ChiP protocols have been described showing 
that they are much quicker (one day procedure) and moreover, they require a lesser 
number of cells in comparison to standard protocols (Dahl and Collas, 2008). Due to 
micro ChIP techniques, it is possible to use tiny amounts of frozen tissue sections. Micro 
ChIP can be particularly helpful when tissue is small in quantity. This can be of potential 
in patient targeted therapeutics where sample load is small, like an image guided biopsy 
(Brehar et al., 2012). 
AptaBid (Aptamer-facilitated Biomarker Discovery) is another technique described for 
biomarker discovery. It has been described from the nascent stage of generating DNA 
aptamers to target molecules using SELEX and they are used to isolate biomarkers from 
the cells. The isolated biomarkers are identified by means of mass spectrometry and it 




Currently, there is no documented method for performing biomarker discovery except 
AptaBiD, which was performed using dendritic mouse cells (Berezovski et al., 2008). 
There is no previously published work for aptamer associated biomarker discovery in 
glioma except the outcome paper from this thesis (Aptekar et al., 2015) as published in 
2015. There remains a potential for developing a pull-down protocol to recognise 
potential biomarkers in glioma and establishing a working methodology.  
1.7 Rationale of the project 
The aim of this project was to develop a novel pull-down assay to identify the target 
ligands of aptamers generated against different glioma cell lines. Current treatment 
protocols for GBM is based on suitable surgical excision followed by chemo and 
radiotherapy. GBM is incurable and current treatment helps to increase meaningful 
survival (NICE, 2019). Patients with GBM still continue to have poor prognosis and long 
term outcomes (Krex et al., 2007). Despite multiple chemotherapeutic agents in the last 
decade being used in various trials, GBM survival has increased to 14 months. By being 
able to develop an assay to identify the target ligands, new patient specific targeted 
therapy could be developed. Aptamer selection against unknown targets is already 
established but no specific assay exists which can help identify the target molecule. 
1.7.1 Aim of the Project 
The main aim of this study was to develop a protocol for aptamer assisted precipitation. 
This will help for identifying target proteins, which are responsible for attachment with 
‘aptamers’. These are likely to be glial specific. Furthermore, the study was designed to 
extract, isolate and characterize these target cell proteins and validate the novel ‘pull-




1.7.2 Specific Aims 
• To test glial specific aptamers already published in literature and to assess specificity 
towards various cell lines 
• To use tissue culture techniques of fluorescent microscopy and immunostaining and 
assess binding of such aptamers for primary cell culture using confocal microscopy 
and biotin tagged aptamers. 
• To develop an aptamer-assisted precipitation protocol and to extract the cell 
complex binding to the aptamers using cell lysis and Modified Chromatin 
Immunoprecipitation (ChIP) 
• To identify the cellular complexes isolated using mass spectroscopy 
• To analyse the data and to confirm target pull-down using Western blotting and 
staining with specific antibodies 
• To confirm the validity of the protocol and expanded application to other aptamer-
cell complexes. 
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2 Materials and methods  
2.1 Introduction 
The experiments were carried out using different grades of immortalised human glioma 
cell lines; U87MG (grade IV glioblastoma), 1321N1 (grade II astrocytoma) and non-
cancerous foetal astrocytes SVGp12. The cell lines were obtained from the European 
Collection of Cell Cultures (ECACC), UK and American Type Culture Collection (ATCC). 
Normal human astrocyte short term cultures were used during later parts of the 
experiments. Short term cultures from patient biopsies obtained from the Brain Tumour 
North-West (BTNW) consortium tissue bank  
2.2 Media and supplements 
The media and supplements were used for specific cell lines according to recommended 
guidelines of ECACC and ATCC. Media for the short-term cultures was used as per 
established protocols from BTNW guidelines (Appendix 2). The preparations were 
carried out under aseptic conditions. All cell lines were grown in 75 cm2 or 25 cm2 tissue 
culture flasks (Thermo Scientific, UK) and maintained in a 37°C humidified incubator, 
with 5% CO2. For the experiments in the study, the cell lines were harvested at 70-80% 
confluence and used between passages 5-25. Short term cultures were used between 
passages 3-13. All plasticware was obtained from Fisher scientific, Leicestershire, UK, 
media and supplements from scientific laboratory supplies (SLS), Lonza, Nottingham, UK 
and reagents from Sigma-Aldrich Ltd, Butterworth, UK. 
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2.3 Cell culture with commercial cell lines 
2.3.1 Commercial cell lines  
Monolayer of cells at 70-80% confluency were subcultured. The U87MG and SVGp12 cell 
lines were grown in Essential Minimum Eagle Medium (EMEM) supplemented with 10% 
(v/v) FBS, 2 mM L-glutamine, 1 mM sodium pyruvate and 1 % (v/v) non-essential amino 
acids (NEAA), while the 1321N1 cell line was maintained in Dulbeccos’s Modified Eagle’s 
Medium (DMEM) supplemented with 10% (v/v) foetal bovine serum (FBS) and 2 mM L-
glutamine. The media was aspirated and the cells were washed with 0.1 M phosphate 
buffered saline (PBS) (pH 7.41), twice, to remove any traces of serum from the cells. The 
cells were detached by incubation with 0.25% trypsin for 2 minutes at 37°C humidified 
incubator, with 5% CO2. The flask was then tapped gently and viewed under the inverted 
light microscope to ensure the detachment of cells. Complete medium was then added 
to neutralise the reaction and mixed gently but well, to obtain a homogenous and evenly 
distributed cell suspension. The cells were seeded at the ratio of 1:4 to each fresh flask. 
These cell cultures were observed regularly and sub-cultured at 70-80% confluency. 
2.3.2 Freezing cultures for storage 
Cell flasks with confluent cultures were passaged as above. After trypsinising cells, 
complete medium was then added to neutralise the reaction and mixed gently but well, 
to obtain a homogenous and evenly distributed cell suspension. This suspension was 
centrifuged at 200 x g for 5 minutes to get a cell pellet. The supernatant was aspirated 
and the cell pellet suspended in 10ml of media. Cell count was performed using coulter 
counter (Beckman coulter Z1, serial AK03015). The cell count enables dividing cells 
optimally for storage at a million per vial. The appropriate cell dilution is achieved and 
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suspended in 1ml of freezing solution, made from 750µl of FBS and 250µl of DMSO 
(dimethyl sulfoxide). The cell suspension was then put in a freezing container, Mr 
FrostyTM (Thermoscientific, UK) and put in -80⁰C. The container has isopropyl 
alcoholwhich enables cooling the cells at -1⁰C per minute and keeping them viable. The 
cells were left for 24 hrs and then transferred to liquid nitrogen for longer storage. 
2.4 Short term culture 
Fresh tissue from the surgical biopsy was collected from the neurosurgical theatres at 
the Royal Preston Hospital in transport media (2 mM penicillin and streptomycin 
combined at 0.5% and amphotericin at 0.5% in DMEM (Dulbeco’s Modified Eagle’s 
Medium)). The specimens were processed immediately in most cases, the rest being 
store at 4⁰C in the fridge for processing the following day. The tissues were processed 
in a class III ventilation hood (Holten HA243 BS and Jouan MSC 9) and transferred into a 
petri dish. The tissue was weighed in the primary culture lab and segregated into like for 
like sections using sterile scalpel blades and forceps. Ample tissue for diagnosis was 
taken and the residual tissue weighed again prior to being divided for culture and frozen 
sample. A final research tissue weight was recorded. Tissue for culture was diced and 
cut into small parts and washed with culture media, F10 Ham containing FBS. Penicillin 
and streptomycin combined (2 mM) and amphotericin (2 mM), both at final dilution at 
0.5% was added to the initial culture media wash. The wash was performed to remove 
the dead and necrotic tissue accompanying the tissue sample and repeated three times 
with centrifugation for 30 seconds at 200 x g. 
The tissue sample at the end of washes was either disaggregated using 50 U/ ml 
collagenase in 9ml volume of tissue suspension. This was done in a T25 flask at 37⁰C with 
regular shaking to enable good disaggregation for 4-5 hours. The disaggregate at the 
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end was gently pipetted a few times and then centrifuged at 200 g for 5 minutes before 
removing the supernatant and putting into culture with fresh culture media at 37⁰C in a 
new T25 flask. Fresh media was added to the disaggregation T25 flask as well and put at 
37⁰C. In cases of small amounts of tissue being available for culture, the tissue was 
washed and placed as an ‘explant’ (Freshney, 2006) into T25 flasks in fresh media for 
culture at 37⁰C. After 24-48 hours, the media and non-adherent cells were removed and 
put into another T25 flask with fresh media to enable further culture growth. The media 
flask with primary disaggregation and explant would then have fresh media added and 
checked every 3-4 days. Media was changed at varying intervals when the colour of the 
original media in the flask faded and corresponded with growth in cultures. Half media 
change was performed at these times to ensure the media was not completely devoid 
of both endogenous and exogenous growth factors. 
Table 2-1  Short term cultures and their source 
Cell Line Source Glioma Grade 
BTNW911 BTNW GBM 
BTNW914 BTNW GBM 
BTNW370 BTNW Gliosarcoma 
IN1528 Wolverhampton GBM 
IN1612 Wolverhampton GBM 
W2045 Wolverhampton GBM 




2.5 Immunochemistry characterisation of short-term cell cultures 
Immunostaining for short term cultures was performed using antibodies, GFAP (glial 
fibrillary acidic protein), EMA (epithelial membrane antigen) and CD34 (cluster of 
differentiation 34 protein) (Fina et al., 1990) as detailed in Table 2.2.  
Table 2-2 List of antibodies and dilutions for characterisation of short-term cultures 
Antibody/target Dilution Manufacturer Type 
GFAP 1:400 Abcam, UK Rabbit polyclonal 
EMA 1:350 Dako, UK Rabbit polyclonal 
CD34 1:300 Dako, UK Rabbit polyclonal 
Biotinylated 
secondary Antibody 
1:500 Abcam, UK Rabbit polyclonal 
 
This was to confirm neural or glial tissue in origin (GFAP), absence of meningothelial cells 
(EMA) and absence of endothelial cells in origin (CD34). Immunostaining was performed 
using Vectastain® ABC kit (Vector Labs, USA) and immunocytochemistry protocol. Cells 
were grown in chambered slides and seeded at 10,000 cells per well. Cells were grown 
for 48 hrs and checked under a microscope for confluency. Excess media was removed 
and the slide washed with 10 mM tris-phoshate buffer saline (TBS) three times for 5 
minutes each. The cells were then fixed with acetone methanol solution at 1:1 dilution, 
pre-chilled to -20⁰C and kept at -20⁰C for 10 minutes. Excess fixative was removed and 
cells were air dried and rehydrated with TBS. The cells were blocked with horse serum 
for 20 minutes and washed with TBS three times. Antibodies at manufacturer specified 
dilution was then added to the respective slide wells and incubated for 30 minutes at 
room temperature (except GFAP, incubated overnight at 4⁰C). The excess antibody was 
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washed away and the slides washed with TBS three times. The secondary antibody from 
vectastain® kit was added to the chambers and incubated at room temperature for 30 
minutes. The secondary antibody was then washed off and 200 uµ of Strep AB Complex, 
premixed and standing for 30 minutes was added to the chambers for 30 minutes. At 
the end of 30 minutes, ABC complex was removed and cells washed three times with 
PBS/TBS. Fresh DAB solution at dilution of 50 µL to 1ml of buffer was added to the 
chambers for 5-10 minutes. This was then washed off and cells were counter stained 
with haematoxylin for 20 seconds. This was washed in running water bath and then 
sequentially quenched with graded alcohol. The chamber was then removed using the 
special tool provided and slide rinsed finally in xylene and mounted with DPX 
(Thermoscientific, UK), a synthetic mounting resin and a large coverslip. DPX is a mixture 
of polystyrene, plasticizer and xylene. 
2.6 Characterisation of cell lines 
Cell cultures of U87MG, 1321N1and SVGP12 were grown in six well plates on standard 
cover slips to 80% confluence prior to characterisation. The coverslips were washed 
three times with PBS. The cells were then fixed using 4% paraformaldehyde (PFA) for 
15-20 minutes. After fixation, the cells were washed three times with 0.1 M PBS (pH 7.4) 
for 5 minutes each and then blocked using 10% goat or donkey serum for 1 hour. Cells 
were again washed three times with PBS and the respective antibodies added to each 
coverslip after placing in separate wells as per manufacturer guidelines and incubated 
at room temperature for 30 minutes (Table 2.3). The excess antibody was washed away 
and the slides washed with PBS thrice. The secondary antibody was added to the 
coverslips and incubated at room temperature for 30 minutes, in the dark. The excess 
antibody was removed and the coverslips mounted on slides and sealed with nail 
43 
 
varnish. Images were taken on Zeiss LSM 510 laser scanning confocal microscope 
(excitation at 488 nm; emission at 543nm laser).  
Table 2-3 List of antibodies and dilutions for characterisation of cell lines 
Antibody/target Dilution Manufacturer Type 
GFAP 1:300 Abcam, UK Rabbit polyclonal 
HLA 1:250 Abcam, UK Rabbit polyclonal 
VEGF 1:200 Abcam, UK Rabbit polyclonal 
Isotype control 1:100 Santacruz, UK Rabbit polyclonal 
Alexa Fluor 488 2⁰ 
ab 
1:1000 Life technologies, 
UK 
Goat, anti rabbit 
 
2.7 Binding of fluorescent tagged aptamer to cell lines 
2.7.1 Live cell incubation with Cy3 tagged aptamer. 
To evaluate the binding of fluorescent Cy3 tagged aptamers, SA44 DNA (Aptekar et al., 
2015), SA43 DNA and SA56 RNA (IDT, UK) (table 2.4 and novel TDM aptamers table 2.5); 
cell cultures of U87MG, 1321N1 as glioma cell lines and SVGP12 as control were used. 




Table 2-5 Novel TDM aptamer sequences 
 
The cells were grown in six well plates on standard cover slips. The cells were grown to 
80% confluence prior to treatment with the aptamer then washed with PBS at 37⁰C. The 
aptamers were diluted with respective media to achieve a final concentration of 100nM 
in 1 ml.  The cells were incubated with the aptamer in dark for 90 minutes followed by 
removal of the media and sequentially washed three times with PBS for 5 minutes each. 
The cells were then fixed using 4% PFA for 15-20 minutes. This was followed by another 
three washes with PBS for 5 minutes each. The coverslips were then mounted on glass 
slides with 10 μl of DAPI (4',6-diamidino-2-phenylindole) upside down and the edges 
sealed with nail varnish to prevent drying of the cells and DAPI. The slides were imaged 
under confocal microscope (Zeiss LSM 510 laser scanning confocal microscope) at 20x 
and at 40x using the oil based lens (excitation at 543 nm; emission at 560-615nm laser) 
once the coverslips were immobile. 
2.7.2 Fixed cell incubation with Cy3 tagged aptamer. 
 The cells were grown (see section 3.2 for details) and were fixed with 4% PFA prior to 
aptamer treatment. After fixation, the cells were washed three times with PBS for 5 
minutes each and then blocked using 10% goat or donkey serum for 1 hour. This was 
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then again washed three times with PBS and the aptamer incubated for 90 minutes. The 
cells were then washed three times with PBS and then mounted on slides using DAPI in 
the dark and visualised using confocal microscopy, using the same settings as Section 
2.7.1. 
2.8 Aptamer chemistry with biotinylated aptamer 
Aptamer binding was determined using biotinylated aptamers to commercially available 
cells lines and patient derived short-term cultures. Biotinylated aptamers were utilised 
to establish binding affinity of aptamers seen with fluorescent tagged aptamer, as the 
biotin tag would be utilised in the aptamer assisted precipitation of target molecule. 
Commercial cell lines were used to develop the protocol and then the protocol was 
applied to short-term cultures. Fixed and live cells were both used to evaluate binding 
with biotin conjugated aptamers. 
2.8.1 Biotinylated aptamer binding to live cells 
Commercial cell lines U87MG and SVGP12, were grown in chambered slides (FalconTM 
chambered slides, Fisher scientific, UK) to 80% confluence. The chambers were seeded 
with 30-40,000 cells and utilised for aptamer binding the following day. The media was 
removed and fresh media with aptamer at dilution of 100nM was added to the slide and 
incubated at 37⁰C for 90 minutes. Excess media was removed, and the slide washed with 
0.1 M PBS or Trisphoshate buffer (TBS) three times for 5 minutes each. The cells were 
then fixed with acetone methanol solution at 1:1 dilution, pre-chilled to -20⁰C and kept 
at -20⁰C for 10 minutes. Excess fixative was removed, cells were air dried and then 
rehydrated with PBS/TBS. The cells were blocked with 10% horse serum for 20 minutes 
and washed with TBS three times.  Approximately 200µL of Strep AB Complex from the 
VectastainTM kit, premixed and standing for 30 minutes was then added to the chambers 
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for 30 minutes. At the end of 30 minutes, ABC complex was removed and cells washed 
three times with PBS/TBS. Fresh DAB (diaminobenzidine) solution at dilution of 50µL to 
1ml of Buffer was added to the chambers for 5-10 minutes. Diaminobenzidine works by 
amplification of the signal by multiplying the avidin-biotin (Viens et al., 2004) to achieve 
a brown stain. This was then washed off and cells were counter stained with 
haematoxylin for 20 seconds. This was washed in running water bath and then 
sequentially quenched with graded alcohol. The chamber was then removed using the 
special tool provided and slide rinsed finally in xylene and mounted with DPX and large 
coverslip. 
2.8.2 Biotinylated aptamer binding to fixed cells 
The above protocol as in section 2.8.1 was followed for cell culture and aptamer 
incubation. After media removal, the cells were washed with PBS and fixed with 
paraformaldehyde solution (PFA) at 4 % dilution at room temperature for 10 minutes. 
Excess fixative was aspirated and the slides washed with PBS. The cells were then 
incubated with 0.1% triton X100 to permeabilise the cells for 5 minutes at room 
temperature. Excess fluid was then aspirated and washed again with PBS three times. 
The cells were blocked with 10% horse serum for 20 minutes and washed with TBS three 
times.  The aptamer at 100nM dilution in PBS was then added for 60 minutes at room 
temperature. The rest of steps for ABC and DAB staining were followed as in section 
2.8.1. The slides were then quenched with alcohol and mounted using DPX as in section 
2.8.1. 
2.8.3 Changes to staining methodology with AB Complex and DAB 
ABC staining method was altered to assess if better visualisation could be achieved. ABC 
staining works by amplification of the signal by multiplying the avidin-biotin complexes 
47 
 
(Spencer et al., 2003; Viens et al., 2004), which undergo a reaction with 
diaminobenzidine to generate a brown stain. One avidin molecule has the capacity to 
bind to four biotin molecules, hence resulting in the amplification (Livnah et al., 1993). 
Due to the primary target in the experiment being biotin (biotinylated aptamer), 
premixing AB complex could result in slightly less availability of avidin for binding. Hence, 
the experiment was altered from the protocol described in Section 8.1 at the ABC stage. 
Avidin complex was first incubated with the cells after fixation, instead of premixing 
avidin and biotin (A and B). After reacting the avidin for 15 minutes, the excess was 
aspirated and the slide washed with PBS. Biotin was then incubated with the slide at 
room temperature for 15 minutes. Fresh DAB solution was also diluted to 50µl to 1.5ml 
dilution. The rest of the protocol was as in section 2.8.1. 
2.8.4 Biotinylated aptamer on fixed commercial cell lines and short-term 
cultures 
Cell lines were cultured as in section 2.8.1. At 80% confluence, the cells were fixed with 
4% PFA at room temperature for 10 minutes. Excess fixative was aspirated and the slides 
washed with PBS. The cells were then incubated with 0.5% triton X100 to permeabilise 
the cells for 5 minutes at room temperature. The cells were blocked with 10% horse 
serum for 20 minutes and washed with PBS three times The cells were washed again 
with PBS three times and then incubated with aptamer at 100nM dilution in PBS at room 
temperature. After incubation, the cells were washed with PBS three time and 
proceeded for ABC staining as in section 2.8.1.  
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2.9 Methods of Protein extraction  
2.9.1 Protein extraction techniques for fixed cells with RIPA buffer 
Cells were cultured in T75 flasks to 80 % confluence followed by washing with PBS and 
fixed with 4% PFA at room temperature for 20 mins. The cells were then washed with 
PBS three times and scraped from the flasks in the presence of RIPA 
(radioimmunoprecipitation) lysis buffer (pH 8.0). A total volume of 1ml of the cells and 
RIPA was put in an eppendorf and kept for lysis at 4⁰C for 30-45 minutes. At the end, the 
eppendorf was centrifuged at 4472 x g for 20 minutes at 4⁰C. The supernatant aspirated 
was assessed for protein concentration using Bradford assay (Bradford, 1976). 
Protein extraction was also performed using the above technique until the cells were 
scraped into RIPA lysis buffer. RIPA has the lowest concentration of SDS at 0.1% and is 
least denaturing (Zhang et al., 2015). It also has least interference with the proteomic 
assessment in bradford assay. The following variations for protein extractions were 
attempted: 
a) Freeze and thaw of cell suspension using liquid nitrogen and water bath at 37⁰C 
for eight cycles for optimisation of protein extraction 
b) Heat the cell suspension at 100⁰C for 20 minutes followed by 60⁰C for 2 hours  
c) Pass the cell suspension through a 27 gauge needle attached to a syringe for six 
passes 
d) Water bath sonication of the cell suspension for cycles of 30 seconds, 
interspaced with rest period of 1 minute for 15 cycles 
e) Probe sonication of the cell suspension at 20 hertz for 30 seconds on ice, with 
rest periods of 1 minute for 6 cycles 
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The above lysates were then centrifuged at 4472 x g for 20 minutes at 4⁰C and the 
supernatant was assessed using Bradford assay. 
2.9.2 Protein extraction using various lysis buffers on fixed cells 
Protein extraction was further optimised by using other lysis buffers on fixed cells. The 
following lysis buffers were made  
a) RIPA, containing 2% SDS (pH 8.0) 
b) 2% SDS in PBS lysis buffer (pH 8.0) 
c) 1% SDS in PBS lysis buffer (pH 8.0) 
d) Native lysis buffer (pH 8.0) 
The above lysis buffers were used for fixed cell lysis using the techniques mentioned in 
section 2.9.1 and analysed using Bradford assay for protein dilution. 
2.9.3 Protein extraction on unfixed cells 
Cells were trypsinised and complete medium was then added to neutralise the reaction 
and mixed gently but well, to obtain a homogenous and evenly distributed cell 
suspension. This suspension was centrifuged at 200 x g for 5 minutes to get a cell pellet. 
This cell pellet could be used immediately or stored at -80°C for future use. The cell pellet 
was then resuspended with RIPA buffer to a 1ml volume. The cells were lysed in this 
solution for 45 minutes at 4⁰C on a rotating platform at 2.236 x g (200 rpm). The lysate 
was then centrifuged at 4⁰C for 10 minutes at 4472 x g and the supernatant was assessed 
using Bradford assay, section 2.10. 
Extraction was finalised for pull-down using triton X100 at 0.1% dilution to avoid 
denaturation of proteins with RIPA and SDS. Using triton X100, maintains the proteins 
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in a native state and enable specific pulldown. Triton X100 also has less interference 
with Bradford reagent and hence gave a more accurate protein estimation. 
2.10 Bradford Assay  
Bradford assay is a method for protein estimation involving the reaction of Coomassie 
brilliant blue G-250 dye to the proteins in the sample (Bradford, 1976). Protein 
standards, made from bovine serum albumin (BSA) were made. They had a dilution of 
0.2 to 2 mg/mL and were used as a reference. Samples and standards were diluted in 
Bradford reagent (Sigma, Poole, UK) (1 in 50 dilutions or 5µl sample to 250µl of Bradford 
reagent). The plate was incubated for 10 minutes on ice to prevent protein degradation. 
The plate was then read using absorbance values, at wavelengths from 590 to 612 nm 
using a plate reader, Enspire by PerkinElmer (Massachusetts, US). Three consecutive 
readings were taken of all the samples. The absorbance of BSA samples was plotted 
against the dilution and a linear standard plot was determined. Cell extract proteins 
were then calculated by respective dilution factors. 
2.11 Method development of aptamer assisted protein pulldown  
2.11.1 Aptamer precipitation using Aptsci kit 
Anti-EGFR aptamer kit (Amsbio/ Aptamer sciences Inc, UK) was used as per protocol but 
supplemented with SA aptamers.  
Aptamer was added to ultrapure water to make a 100nM solution. Cells were washed 
with ice cold PBS twice in a cell pellet and 1X APB (apto-precipitation buffer, custom, 
contents unknown) containing protease inhibitor on ice for 10 minutes. The stock 
solution was stored at -20 to 4ºC. 1µl of stock is added to 20µl of 1X APB and heated for 
5 minutes at 95 0C and allowed to cool at room temp for 20 mins prior to use. Add the 
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above to 1 ml volume of cell lysate (0.95ml lysate and 0.05ml of 20X S1 solution (custom 
buffer, contents unknown)). S1 solution is meant for minimising non-specific binding. 
The contents are then incubated at 4 0C for 2 hours while rotating at 2.236 x g. 
Included beads (custom, specifics unknown) were prepared by washing twice with 0.5ml 
of 1X WB (washing buffer, custom solution, contents unknown) and collect the beads 
with a magnetic stand and remove the supernatant. The reaction mixture was then 
added to the beads and mixed for 10 mins at 4 0C at 2.236 x g. The eppendorfs were 
then placed on a magnetic stand and supernatant discarded. The beads are washed with 
1X WB for 1 minute gently by inverting and collect the beads on the magnetic stand. 
Beads were washed three more times and supernatants discarded. Elution was done 
using 30µl 1X EB (custom buffer for elution, contents unknown) to the tube and mix for 
15 minutes at room temp while mixing at 37 0C. Place tube on magnetic stand and 
transfer supernatant to new tube. The elutent was then run on 10% SDS PAGE gels and 
protein was visualised with Coomassie blue, section 2.12.3  
2.11.2 Aptamer precipitation using magnetic beads 
Cells cultured in T75 flask were trypsinised and centrifuged in a 1.5mL eppendorf for 5 
minutes at 200 x g to form a cell pellet. The supernatant was discarded and the cell pellet 
was mixed with 1 ml of PBS and put into an eppendorf tube for washing and centrifuged 
for 5 minutes at 200 x g. Cell pellets can be used immediately or stored at -80°C for 
future use. The cell pellet was then mixed with 0.1% Triton X100 in cold PBS solution of 
1ml volume and protease inhibitors. The cells were lysed in this solution for 45 minutes 
at 4⁰C on a rotating platform at 2.236 x g. The lysate was then centrifuged at 4⁰C for 10 
minutes at 4472 x g. The supernatant was taken for aptamer assisted precipitation and 
cell debris discarded. Magnetic trial streptavidin beads, dyna beads (Thermo fischer, UK) 
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were used for incubating with aptamer and cell lysate. Two approaches were taken; the 
magnetic beads were first incubated with the aptamer, with the aim of conjugating the 
aptamer to the beads, and then the aptamer-bead conjugate was incubated with the 
cell lysate. The second approach was to incubate the cell lysate with the aptamer 
followed by incubation with the beads for 45 minutes at 4⁰C. At the end of the reaction, 
the beads were washed with cold PBS three times and separated on a magnetic 
separator. The beads at the end of the final wash were boiled in 5x SDS sample buffer 
for 5 minutes at 95⁰C. 15µl of the boiled AP (aptamer pulled precipitate) and Input 
(whole cell lysate) were then run on 10% SDS PAGE gels and protein was visualised with 
Coomassie blue, section 2.12.3  
2.11.3 Aptamer precipitation using streptavidin agarose beads 
Aptamer precipitation protocol was changed to use streptavidin agarose beads. 
Aptamer was added to the cell lysate and incubated for 45 minutes at 4⁰C. Streptavidin 
agarose beads were taken and prepared by washing with cold PBS three times, lasting 
for 5 minutes each at 4⁰C and centrifuged. These beads were then blocked with BSA for 
2 hours while rotating on a shaker at 200 rpm at 4⁰C. Following the blocking, the beads 
were then washed with cold PBS thrice, lasting for 5 minutes each at 4⁰C. The beads 
were centrifuged and then incubated with aptamer-lysate for 30 minutes at 4⁰C on a 
shaker at 200 rpm. The beads were then centrifuged and washed four times with cold 
PBS on a shaker for 5 minutes each. The beads at the end of the final wash were boiled 
in 5x SDS sample buffer for 5 minutes at 95⁰C. The input sample was prepared by taking 
50µl from the cell lysate and boiled with 50µl of SDS sample buffer for 5 minutes at 95⁰C. 
15µl of the boiled AP and Input were then run on 10% SDS PAGE gels and visualised using 
Coomassie blue, section 2.12.3 
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2.11.4 Aptamer assisted precipitation technique 
The cell pellet was mixed with 0.1% triton X100 in cold PBS solution of 1ml volume. The 
cells were lysed in this solution for 45 minutes at 4⁰C on a rotating platform at 2.236 x 
g.  The lysate was then centrifuged at 4⁰C for 10 minutes at 4472 x g. The supernatant 
was taken for aptamer assisted precipitation and cell debris discarded. An aliquot was 
taken from the supernatant of the eppendorf for Bradford assay and protease inhibitors 
at 1:200 dilution in PBS, was added to the residual lysate. Aptamer was added to the cell 
lysate and incubated for 45 minutes at 4⁰C. Streptavidin agarose beads were taken and 
prepared by washing with cold PBS three times for 5 minutes each at 4⁰C and 
centrifuged at 200 x g. These beads were then blocked with BSA for 2 hours while 
rotating on a shaker at 2.236 x g at 4⁰C.  The beads were then washed with cold PBS 
three times for 5 minutes each at 4⁰C. Sedimentation of beads was performed to remove 
BSA by leaving on an eppendorf rack for 5 minutes. This was performed to reduce non-
specific precipitation and reduce errors. At the end of the aptamer incubation, the 
aptamer-lysate mix was added to the prepared streptavidin agarose beads and 
incubated for 30 minutes at 4⁰C on a shaker at 2.236 x g. At the end of the incubation 
with the beads, they were kept on ice for sedimentation of the beads for 5 minutes and 
the supernatant was removed and kept separately. The beads were then washed with 
cold PBS three times at 4⁰C on a shaker for 5 minutes. At the end of each wash, the 
beads were allowed to settle by sedimentation. The beads at the end of the final wash 
were boiled in 5x SDS sample buffer for 5 minutes at 95⁰C. The input sample was 
prepared by taking 50µl from the cell lysate and boiled with 50µl of SDS sample buffer 
for 5 minutes at 95⁰C. 15µl of the boiled AP and Input were then run on 10% SDS PAGE 
gels and visualised with Coomassie blue (section 5.2). 
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2.12 Western blot for target confirmation 
Western blotting technique was developed for protein separation on gel blocks for mass 
spectrometry analysis and for antigen identification. The initial part of Western blotting 
involves separation of protein according to molecular weight. The latter part is transfer 
of the proteins from gel to nitrocellulose membrane for antigen identification using 
antibodies. In the scope of this thesis, the technique was also modified for aptamer 
binding. 
2.12.1 Sample preparation 
Protein concentration of input samples was determined using a BSA standard curve from 
0.1 mg/ml to 2mg/ml after determining the absorbance using the Bradford assay testing. 
Twenty-five µl of input protein sample at 2mg/ml was mixed with 5x laemmli buffer 
(Sigma, Dorset, UK) (containing 4% SDS, 20% glycerol, 10% 2-mercaptoethanol, 0.004% 
bromphenol blue and 0.125 M Tris HCl, pH approx. 6). at a ratio of 1:1. The eppendorfs 
were heated in a heat block at 95⁰C for 5 minutes, after which, the sample was ready 
for loading into pre-cast or cast 10% polyacrylamide gels (section 2.12.2) for separation 
of proteins prior to mass spectrometry analysis. 
Sample preparation from aptamer assisted precipitation was done using the final aliquot 
eluted from streptavidin beads. After the final wash from aptamer precipitation, 50µl of 
5x laemmli buffer was added to the beads to facilitate detachment of biotin and 
streptavidin. The eppendorfs containing the beads and laemmli buffer were heated in a 
heat block at 95⁰C for 5 minutes after which the sample was ready for loading. 15µl to 
25µl sample was loaded into each of the wells. Exact protein concentration of the final 
extract could not be estimated due to the small size of the elute and interference of SDS 
in the laemmli buffer in Bradford assay.  
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2.12.2 Gel electrophoresis 
 The top loading part of the gel was made of 4% polyacrylamide stacking gel and bottom 
separation or resolving with 10% polyacrylamide gel. An electric current was applied 
across the gel which enabled separation of proteins according to their molecular weight 
and measured against a pre-set ladder with specific molecular weights. The stacking gel 
was poured into the setup and allowed to polymerise with tetramethylethylenediamine 
(TEMED, 10 µL in 10% and 6 µL in 4% gel) and ammonium persulphate (APS, 100 µL  in 
10% and 60 µL in 4% gel). TEMED initiates a polymerising and APS act as a catalyst for 
the chain reaction. Air contact has to be obliterated for this and hence the stack was 
covered with water. After the resolving gel had polymerised, the water seal was 
removed and stacking gel was poured. A well comb was inserted and set in the stacking 
gel to enable creation of sample loading sites. The gels were then placed in an 
electrophoresis tank, filled with 1.5 M tris glycine buffer, at pH 7.4 and the wells were 
loaded with 25µl protein lyste:laemmeli buffer.  The gels were run for 90 minutes at 
120V before being removed for either staining or transfer. 
2.12.3 Gel staining 
The gels were stained with Coomassie blue (Coomassie Blue R-250 0.1% w/v, deionised 
water 50%, methanol 40%, acetic acid 10%) at room temperature for one hour on a 
rotating platform at 0.559 x g. At the end of the staining, the gel was destained using 
destaining solution (deionised water 50%, methanol 40%, acetic acid 10%), changed at 
20-minute intervals. Destaining was stopped when clear stained bands could be 
visualised by the naked eye and background staining removed. The gels were then 
imaged using Geldoc™ imager (Bio-rad Laboratories Inc., Watford, UK) ™ imager (Bio-
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rad Laboratories Inc., Watford, UK)  (Biorad, UK), white light, transwhite setting (302 nm 
excitation). 
2.13 Mass spectrometry analysis 
The protein samples from aptamer assisted precipitation that had been separated by gel 
electrophoresis were cut into bands and chunks. They were appropriately labelled and 
sent to St. Andrews university for mass spectrometry analysis. This was a commercial 
purchase of service and the protocol followed for the analysis is given in Section 2.13.1. 
2.13.1 nLCESI-MSMS (Nano-scale liquid chromatographic tandem mass 
spectrometry ) analysis  
The peptides were concentrated, if necessary, using a SpeedVac (ThermoSavant). They 
were then separated on an Acclaim PepMap 100 C18 trap and an Acclaim PepMap RSLC 
C18 column (ThermoFisher Scientific), using a nanoLC Ultra 2D plus loading pump and 
nanoLC as-2 autosampler (Eskigent). The peptides were eluted with a gradient of 
increasing acetonitrile, containing 0.1 % formic acid (5-40% acetonitrile in 5 min, 40-95% 
in a further 1 min, followed by 95% acetonitrile to clean the column, before re-
equilibration to 5% acetonitrile). The eluent was sprayed into a TripleTOF 5600 
electrospray tandem mass spectrometer (ABSciex) and analysed in Information 
Dependent Acquisition (IDA) mode, performing 250 msec of MS followed by 100 msec 
MS/MS analyses on the 20 most intense peaks seen by MS. The MS/MS data file 
generated was analysed using the Mascot algorithm (Matrix Science) against the NCBInr 
database Aug 2013 with no species restriction, trypsin as the cleavage enzyme, 
carbamidomethyl as a fixed modification of cysteines and methionine oxidation and 
deamidation of glutamines and asparagines as variable modifications. Peptides for 
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proteomic analysis were identified above 95% confidence level and with at least two hits 
were analysed. The proteins identified by LC-MS/MS were uploaded onto PANTHER 
(protein annotation through evolutionary relationship) classification system 
(http://www.pantherdb.org/) to enable analysis of functional and pathway classification 
of the proteins. These categories were then represented in pie charts. 
2.14 Protein Transfer 
Gels that were not used for mass spectrometry analysis were transferred to a 
nitrocellulose membrane. A sandwich of Whatmann filter paper and sponges with a 0.2 
µm nitrocellulose membrane (BioRad, UK) in the middle, was put in transfer buffer (1.5 
M tris glycine buffer, pH 7.4). Transfer was performed for at least 1 h at 90 V in an ice 
bath. The gel needs to be on the negative polarity and the nitrocellulose paper on the 
positive polarity to enable transfer of proteins. 
2.14.1 Antibody probing  
TBS or Tris buffer saline was made using 1mM tris buffer saline with 0.1% tween 20 and 
used for further western blotting experiments. The protein transferred membrane was 
washed with distilled water and incubated with blocking buffered solution, made of 
TBST with 5% milk, for 1 h at room temperature.  Blocking reduces non-specific binding 
of proteins and ligands. After 1 h, the blot was washed with TBST three times, for 10 
minutes each at room temperature. After washing, the appropriate primary antibody 
was incubated, suspended in TBS with 5% milk solution, overnight at 4⁰C (Table 2.6). The 
blot was washed with TBS three times for 10 min each at room temperature, the 
following day. Washing removes the unbound primary antibody and then was incubated 
with secondary antibody for 1 h at room temperature, before washing again with TBS. 
The blot was then reacted with ECL plus kit (GE healthcare, UK) as per manufacturer 
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instructions and imaged using Geldoc™ imager (Bio-rad Laboratories Inc., Watford, UK) 
™ imager (Bio-rad Laboratories Inc., Watford, UK) (Biorad, UK), colorimetric with epi-
white at 302 nm excitation. 
Table 2-6 List of antibodies and dilutions for Western blotting for Ku proteins 
 
2.14.2 Dot blot analysis 
Protein samples made after lysis and aptamer precipitation were used for dot blot 
analysis. 5µl samples containing 2mg/ml of protein were pipetted on the nitrocellulose 
membrane and air dried for 15 minutes. The same samples were repeated with 5µl of 
twice to increase the protein content for detection. After air drying, the membrane was 
washed with distilled water and incubated with blocking buffered solution, made of 
TBST with 5% milk, for 1h at room temperature. After 1 h, the blot was washed with TBS 
three times, for 10 minutes each at room temperature. After washing, the appropriate 
primary antibody was incubated, suspended in TBS with 5% milk solution, overnight at 
4⁰C. The blot was washed with TBS three times for 10 min each at room temperature 
after the incubation period. It was then incubated with secondary antibody for 1 h at 
room temperature, before washing again with TBS. The blot was then reacted with ECL 
plus kit (GE healthcare, UK) as per manufacturer instructions, and imaged using Geldoc™ 
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imager (Bio-rad Laboratories Inc., Watford, UK) ™ imager (Bio-rad Laboratories Inc., 
Watford, UK)  (Biorad, UK), colorimetric with epi-white at 302 nm excitation. 
2.14.3 Dot blot and probing with aptamer 
The above protocol for protein transfer and dot blot was followed until pre-antibody 
incubation. For aptamer incubation, the aptamer was suspended in TBS with 5% milk 
and incubated for 90 minutes. The blot was washed with TBS three times for 10 min 
each at room temperature after the incubation period. AB complex staining was 
performed as per immunochemistry and incubated for 30 minutes. The membrane was 
then washed with TBS three times and incubated with DAB solution for 5 minutes. The 
membrane was then finally washed with TBS and visualised on Geldoc™ imager (Bio-rad 
Laboratories Inc., Watford, UK) ™ imager (Bio-rad Laboratories Inc., Watford, UK)  
(Biorad, UK).  
2.15 Ku70 and Ku80 knockdown and immunostaining 
2.15.1 Ku70 and Ku80 knockdown 
Ku70 and Ku80 knockdown was performed by Farjana Begum Rowther at the University 
of Wolverhampton. Short interfering (si) RNA transfections were facilitated using 
DharmaFECT-1 transfection reagent in a serum containing media and the transfection 
efficiency was assessed using positive control Cyclophilin-B siRNA (Thermo Scientific, 
UK). ON-TARGETplus SMARTpool siRNA targeting human XRCC5 or XRCC6 at 25 nm was 
employed (Dharmacon, GE; UK). In addition, these cultures were transfected in parallel 
with ON-TARGETplus non-targeting siRNA pool at the same concentration (Dharmacon, 
GE; UK). In experiments where combined knockdown of XRCC5 and XRCC6 was 
performed, siRNA at 25nM of both were treated for the specified time as individually. 
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Non-targeting siRNA are abbreviated as siNT. Cells were seeded at 40-50% confluence 
and incubated for 48 hours before commencing transfection to assess the success of the 
transfection. 
For detection analysis, Q-PCR was carried out using TaqMan Q-PCR assay with FAM 
reporter [Thermo Scientific, UK] on an ABI 7500 Sequence Detection System [Applied 
Biosystems].  2µl of cDNA was amplified in a 20µl reaction volume using 1X TaqMan qPCR 
master mix with low ROX [Thermo Scientific, UK] and amplifications were performed in 
triplicate. The XRCC5/6 detection levels were normalised to GAPDH, and the relative 
detection was determined using the 2 
-CT
 method relative to control treatments (siNT). 

























3 Glioma Cell line culture and patient tissue derived short-term 
culture 
3.1 Introduction 
Commercially available cell lines, U87MG, 1321N1 and SVGp12 and short term cultures 
from patient tissue (BTNW 370, BTNW 914, BTNW 911 and IN1077) were used for the 
research. Characterisation and establishment of growth curves is essential to cell culture 
experiments as a pre-requisite (Dang C, 2003; Wadsworth, 2007). During cell culture, 
cross contamination is a major concern for the researcher (Markovic and Markovic, 
1998) and establishment of proper protocol for culture and characterisation of the cell 
lines is important. In terms of commercially available lines, we established that the cell 
lines are glial in origin (GFAP)(Goyal et al., 2015), Human (HLA)(Bergström et al., 1998) 
and show tumour activity (VEGF)(McMahon, 2000). Short term cultures, since grown 
from patient tissue, are characterised by being glial in origin (GFAP)(Goyal et al., 2015), 
are not meningothelial cells (EMA)(Ng et al., 1987) and not endothelial in origin 
(CD34)(Lin et al., 1995; Sidney et al., 2014). Growth curves of the cell lines help in 
establishing the phases of cell growth namely, lag phase, exponential phase and plateau 
phase (Dang C, 2003). This enables one to identify the appropriate cell density for plating 
cells for downstream experiments. 
The aim of the chapter was to characterise the cell lines and the short term cultures and 
establish growth curves to provide information on the growth characteristics of the cells. 
This confirms the appropriate cell density for each cell line and short term culture for 
further experiments.  
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3.2 Growth curves of commercial cell lines 
Growth curves were performed to establish the various phases of cell growth for 
individual cell lines (Figure 3.1). The 1321N1 (human brain astrocytoma), U87MG 
(human brain glioblastoma) and SVGp12 (human foetal astrocyte) were seeded at day 0 
at a density of 2 x 10⁴ cells in T25 flask. Cancerous cell lines U87MG and 1321N1 showed 
exponential growth from day 2 to day 7, giving adequate and optimum cell count from 
day 6 onwards (Figure 3.1A and B). SVGp12 foetal astrocyte derived cell line also showed 
an exponential growth from day 2 to day 6 (Figure 3.1C). There was a reduction in cell 
growth in all cell lines between day 7-8 and likely linked to iatrogenic cause. It could be 
because of a population of cells dying and being replaced by the proliferating subculture. 
Cell growth reached a plateau after day 6 in all cell lines and declined subsequently due 
to over confluence of the flask (Figure 3.1). 
64 
 
1 3 2 1 N 1























U 8 7 M G























S V G P 1 2























G r o w th  c u r v e























1 3 2 1 N 1
U 87M G
S V G P 1 2
 
Figure 3.1 Growth characteristics of U87MG, 1321N1 and SVGp12 cell lines. 
The cell counts were calculated using the trypan blue exclusion assay and counted on a 
haemocytometer from day 0 to day 9. The data points are representative of three 
replicates (n=3) and are presented as mean cell density ± standard error (SE). The 
growth curve showed a lag phase growth from day 0 to day 3 and in exponential phase 
from day 4 to day 7 in U87MG (A), 1321N1 (B) and SVGp12 (C). A reduction in cell 
density occurred on day 7 in U87MG cells (A) and SVGp12 cells (C) and day 8 in 1321N1 
cells. D shows all cell lines plotted on the same axes (red squares=U87MG, purple 
triangles=SVGp12, blue squares=1321N1). U87MG cells showed the fastest 






3.3 Growth curve of short-term cultures 
Short term cultures are derived from tissue donated by the patients. The cells were 
grown in tissue culture flasks after disaggregation of tissue (using collagenase) and 
provided with appropriate physiological conditions to sustain growth. Since tissue is 
heterogeneous, it will need to undergo separation . Cell density of cultures was low 
(Furneaux et al., 2008). Further passaging and subculture was needed to grow short 
term cultures. Forty-two tissue samples were obtained from patients at the Royal 
Preston hospital and put into culture. Very few of the cell cultures were generated and 
utilised for experiments. An example of short term culture growth curve is shown below 
(Figure 3.2).  
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Figure 3.2 Growth curve of IN077, a short-term culture from a grade IV glioma. 
Cell counts were obtained using a coulter counter from day 0 to day 9. The data points 
are mean cell counts (±SEM) from n=3 replicates. The growth curve shows growth from 
day 0 to day 4 and in a plateau phase from day 6 onwards. This is different from 
commercial cell lines where a clear exponential phase is evident.  
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IN077 cells were previously stored from a tissue sample and a growth analysis was done 
to guide protein extraction and experimental timing from short term cultures. Further 
attempts from other short term cultures totalling five in number (BTNW 911, BTNW 913, 
BTNW 914, BTNW 915, BTNW 370) and normal human astrocytes (NHA) was made but 
growth was slow. 
 
3.4 Characterisation of commercial cell lines 
Cell lines were characterised by evaluating GFAP, HLA and VEGF detection by 
immunofluorescence. This is done to ensure that in the process of repeated passages, 
no cross contamination has occurred. In terms of commercially available lines, we 
established that the cell lines are glial in origin (GFAP), Human (HLA) and show tumour 





Figure 3.3 Detection of HLA-I, GFAP and VEGF antigens (green) in cultured 1321N1, 
U87MG and SVGP12 cells.  
A, B, and C represent detection of HLA-I, GFAP and VEGF counterstained with DAPI 
(nuclear stain) respectively, in U87MG cells. D and E represent isotype control and 
control, counterstained with DAPI (nuclear stain) respectively, in U87MG cells. F, G and 
H represent detection of HLA-I, GFAP and VEGF counterstained with DAPI respectively, in 
1321N1 cells. I and J represent isotype control and control, counterstained with DAPI 
respectively, in 1321N1 cells. K, L and M represent detection of HLA-I, GFAP and VEGF 
counterstained with DAPI respectively, in SVGp12 cells. N and O show isotype control and 
control, counterstained with DAPI respectively, in SVGp12 cells. Scale bar = 20 μm. 
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3.5 Characterisation of short-term cultures 
Short term cultures established from patient glial tissue were characterised to confirm 
the cell type. Patient derived short term cultures were categorised as early passage up 
to P3, mid-passage up to P7 and late passage up to P12. GFAP was used to confirm for 
glial cells, epithelial membrane antigen (EMA) as a marker for meningothelial cells and 
CD34 for endothelial cells. Due to the high possibility and ease of growing endothelial 
cells, CD34 was used to exclude cultures that exhibited a high proportion of endothelial 
cells.  
The BTNW914 culture at early passage 3 showed a heterogeneous cell population and 
expressed both GFAP and CD34 (Figure 3.4, A-E). At mid passage 7, the cells showed 
strong staining for GFAP, indicating a continued detection for GFAP and faint brown 
stain for CD34 (Figure 3.4, F-J). At passage 12, the cells showed faint staining for GFAP 
and no staining for CD34 (Figure 3.4, K-O). EMA did not show any significant staining at 
any stage, thus excluding presence of meningothelial cells. The cells did not show any 
staining in the isotype or negative control at any of the passages. 
The BTNW370 at passage 3 showed detection of GFAP, and for CD44, but no staining for 
EMA. (Figure 3.5, A-E). At passage 7 the cells staining for GFAP and no staining for CD44 
or EMA (Figure 3.5, F-J). At passage 12, GFAP was still positive with absence of CD34 and 




Figure 3.4 Detection of GFAP, CD34 and EMA in patient derived short term cultures at 
various stages of passage in BTNW 914 
Cells stained with GFAP, EMA and CD44 at early passage (P3) (A-E), mid passage (P7) (F 
to J) and late passage (P12) (K to O). Cells were counterstained with haematoxylin. The 
isotype control was a rabbit IgG primary antibody (D, I, and N) and control was no 
primary antibody (E, J and O). All cells were counterstained with haematoxylin. The 
detection of GFAP (A, F & K) decreased with increase in passage number (A). The cells 
showed reduced detection of CD44 (B, G) and EMA (C) in later passages representing 
the mixed nature of cultures in early passage for CD34 (L) and EMA (H & M). Scale bar 




Figure 3.5 Detection of GFAP, CD34 and EMA in patient derived short term cultures at 
various stages of passage in BTNW 370 
Cells stained with GFAP, EMA and CD44 at early passage (P 3) (A-E), mid passage (P7) 
(F to J) and late passage number (P12) (K to O). The cells were counterstained with 
haematoxylin. The isotype control was a rabbit IgG primary antibody (D, I, and N) and 
control was no primary antibody (E, J and O). All cells were counterstained with 
haematoxylin. The detection of GFAP (A, F & K) decreased with increase in passage 
number (A). The cells showed reduced detection of CD44 (B, G) representing the mixed 
nature of cultures in early passage for CD34 (L). There was no detection of EMA seen in 


















Growth characteristics show that U87MG and 1321N1 cell lines exhibit exponential 
phase from day 2 to 7 (Eyvazzadeh et al., 2015) and SVGP12 showed exponential phase 
from day 2 to 6. As expected, the U87MG and 1321N1 cell lines exhibited an epithelial 
morphology (Machado et al., 2005) while the non-cancerous SVGp12 cell line showed 
fibroblastic morphology (Baba et al., 2007). Further characterisation determined the 
commercial cell lines were human in origin, of glial origin and U87MG and 1321N1 were 
cancerous.  
Growth curves in short term cultures are difficult to be standardised due to the 
indeterminate nature of cell growth and apoptosis (Mitra et al., 2013). Short term 
cultures are also difficult to grow and maintain due to variable nature of cell type 
(Freshney, 2006; Kaur and Dufour, 2012). The growth curve in short term cultures is not 
consistent between passages and hence an example growth curve of IN077 was 
performed during the initial stages of the project. Short term cultures, characterised 
with GFAP, CD34 and EMA showed that the cells grown from patient tissue were of glial 
tumour origin. This was confirmed by DAB staining, evident with brown staining 
pertaining to antigen-antibody reaction. The lack of positive staining in the isotype 
control showed that the antigen-antibody staining was specific.  
Characterisation is essential prior to commencing work on cell biomarker discovery due 
to various reasons. It is important to ensure the various phases of cell growth namely, 
growth phase and lag phase (Dang C, 2003). Cells in lag or plateau phase may lack the 
functional isotope of interest and can generate negative or false positive results. Gos et 
al (2005) showed upregulation of Wnt6, uPar, Tdag51, Egr1, Ini1a and Mor1 in confluent 
C3H10T1/2 cells and Cancela et al (1997) showed that matrix proteins were significantly 
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altered during different growth phases of normal rat kidney cells. Growth curves 
established the optimal incubation time for the aptamers to be added to the cell 
cultures. Commercial cells were harvested in their exponential growth phase from day 
3 to 6 for all further experiments in the thesis. 
Short term cultures are used after establishing experimental protocol with cell lines to 
validate the results. Cell lines over the years of use can be contaminated or lose certain 
genetic characteristics (Nardone, 2007; Capes-Davis et al., 2010; Allen et al., 2016). To 
counter false results and failure of further research, it becomes important to validate 
results with patient derived cultures.  
Cell lines have the advantage of being readily available, cost effective and easy to 
maintain with mostly known growth pattern (Kaur and Dufour, 2012). There also exists 
plenty of information to corroborate the data and thus help in setting up research in less 
time (Gazdar et al., 2010). They also give consistent results. However, the cell lines do 
not reflect actual tumour physiology (Kaur and Dufour, 2012) and treatment response 
is not representative of in vitro conditions. Cell lines also tend to form a distinct group, 
which is different than their respective tissue (Lukk et al., 2010)  Short term cultures 
represent, in early stages, a heterogeneous population of cells, close to the original 
parent tumour tissue (Gazdar et al., 2010). After initial passages, they too develop into 
subcultures of cell population but still carry a better representation of tumour cells. 
There is also the elimination of using a contaminated cell line (Capes-Davis et al., 2010) 
but user handling is also a factor.  In vitro cancer models are needed to support the 






Chapter 4  
74 
 
4 Confirmation of aptamer binding to glioma cells 
4.1 Introduction 
Aptamer binding to cells needs to be established as a proof of concept, prior to 
identification of the target in glioma cells. The SA43 and SA44 aptamers used here were 
adapted from GL43 and GL44 aptamer sequences detailed in the paper by Cerchia et al 
(Cerchia et al., 2009). GL43 and GL44 were generated by SELEX against U87MG cells and 
shown to be specific to glioma tissue (Cerchia et al., 2009). GL44 and GL43 were 
specifically chosen due to their low Kd (dissociation constant) which implies greater 
binding affinity to the target and hence greater specificity (Bisswanger, 2008).  
It is the 3D structure of aptamers which bind to the target ligand with varying affinity 
(Pan and Clawson, 2009) and can be affected by van der Waals forces, hydrogen bonding 
and ionic interaction (Hermann and Patel, 2000; Long et al., 2008; Ruigrok et al., 2012). 
All aptamer interactions do not use those interactions but the affinity is affected by the 
size of the aptamer, temperature and physiological state of interaction. The larger the 
size of the aptamer, the greater is the number of 3D structures it can form and hence be 
more non-specific (Pan and Clawson, 2009). To increase specificity, a shorter aptamer 
sequence is desired. 
Since the specific part of the aptamer sequence is the aptamer with the loop end rather 
than the attached primers, the GL43 and -44 aptamer sequences were truncated 
without the primers to generate two shortened aptamers to be 43 and 44 nucleotides 
long instead of another 40+ nucleotides attached as primers.  SA43 and SA44 contain 
the DNA homolog of the unique GL43 and GL44 nucleotide sequences, but do not 
contain the primer sequences at the 3’ and 5’ ends, therefore “SA” denotes “shortened 
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aptamer”. Cerchia et al also used truncated aptamers from GL44 and GL43 but shorter 
than 40 bases (Cerchia et al., 2009). SA56, another shortened aptamer from Cerchia et 
al was used which is an RNA aptamer. DNA and RNA aptamers are similar in function but 
vary in their stability (Zhu et al., 2015). RNA have a reactive hydroxyl group (-OH) which 
is susceptible to hydrolysis and degeneration of RNA. DNA on the other hand is relatively 
stable due to C-H bonding (Zhu et al., 2015). RNA is much smaller than DNA by about 
10ᶟ to 10⁶ times and more likely to cross the blood brain barrier (Germer et al., 2013),  
and is therefore perhaps more favourable to use as targeted therapy to the brain (Que-
Gewirth and Sullenger, 2007). SA56 aptamer is a 43-nucleotide base aptamer and was 
used as a comparison for assessing RNA aptamer binding, similar to SA43 DNA aptamer. 
SELEX was used to identify the aptamers. Positive selection was towards U87MG and 
counter-selection (or negative selection step) against T98G cell line by Cerchia et al. 
T98G cell line (Stein, 1979) originated from T98G glioblastoma cell line and is a polypoid 
variant (Coward and Harding, 2014). T98G cells are not capable of forming tumours in 
nude mice, and were therefore considered less tumourigenic and a suitable counter 
selection cell line by Cerchia et al. (2009). 
The first aim of this chapter was to demonstrate aptamer binding affinity in vitro to 
glioma cell lines as determined by fluorescent confocal imaging using Cy3 as a 
fluorophore conjugated to the aptamers.  Aptamer binding also needed to be assessed 
using biotin tagged aptamer (Starikov and Nilsson, 2002), as biotin would be the tag used 
for aptamer precipitation in downstream experiments (Viens et al., 2004; Lee et al., 
2006).  Since the second aim is to show translational clinical relevance, the affinity of 
SA43 and SA44 was also assessed in short term patient derived cultures (Farr-Jones et 
al., 1999; Furneaux et al., 2008).  
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To confirm selective binding of the shortened aptamers, control aptamers were also 
synthesised and consisted of random nucleotide sequences of equivalent composition 
of bases. The reason was to ensure that the aptamer binding was specific and no known 
negative control existed. Random control sequences should either bind to other targets 
or not bind at all. Spiegelmers {Eulberg, 2003 #2705} are biostable aptamers and 
essentially mirror image aptamers which take a hair pin bend. They are likely to reduce 
non-specific binding. The control aptamers used in the project were not spiegelmers, 
hence they should display differential binding and labelled SAneg1 and SAneg2 and their 
structures are discussed in chapter 5.3.  
4.2 Confocal imaging of aptamer uptake 
Live U87MG, 1321N1 and SVGp12 cell lines were incubated with SA44, SA43, SA56 RNA, 
SAneg1 and SAneg2. Cells were grown on coverslips and incubated with Cy3 tagged 
aptamer at physiological conditions in the dark. After a 90 minute incubation, the cells 
were washed and fixed with 4% PFA. They were then dehydrated and mounted on glass 
slides using DAPI and imaged using confocal microscopy.  Aptamer binding was greater 
in U87MG and 1321N1 cell lines compared to the SVGp12 cell line (Figure 4.1, 4.2 and 




Figure 4.1 Confocal imaging of live U87MG cells with 100nM Cy3 tagged SA43, SA44 
and SA56 RNA aptamers.   
Aptamer binding was observed in the cytoplasm of U87MG cells after live incubation 
with each aptamer (A, D and G).  Minimal aptamer uptake was observed with SANeg1 
and SANeg2 (M and P) and no fluorescence was detected with no aptamer control (J).  
Cells were counterstained with the nuclear dye DAPI (B, E, H, K, N and Q).  C, F, I, L, O and 
R show merged images of Cy3 and DAPI staining.  Cells were viewed with a confocal 
microscope at 40x with an oil assisted lens. Scale bar = 20µm 
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Figure 4.1 shows images obtained using confocal microscopy with fluorescent tagged 
aptamers. Image (a) and (d) show extensive uptake of the Cy3 labelled aptamer SA44 
and SA43 by the U87MG cell line respectively. The binding appears to be different 
compared to 1321N1 cell line (Figure 4.2) and a clear haloing of the nucleus can be seen 
(images (c) and (f) marked with arrow). The aptamer binding appears to be greater in 
the cytoplasm and likely on the surface membrane compared to the nucleus. Few cells 
show greater binding compared to others in the same image and could likely be a result 
of cells being in various stage of the growth cycle. Image (g) shows greater binding of SA 
56 RNA aptamer to the U87MG cell line compared to 1321N1 (Figure 4.2). Image (j) 
shows the control without any fluorescence. Images (m) and (p) show a very faint signal 
with SANeg1 and SANeg2 aptamer when compared to 1321N1 (Figure 4.2) cell line. 
SANeg1 and SANeg2 were random sequence aptamers generated as a control for the 
project. There was differential biding in the SANeg1 and SANeg2 aptamers when 





Figure 4.2 Confocal imaging of live 1321N1 cells incubated with 100nM Cy3 tagged 
SA43, SA44, SA56 RNA aptamers.  
SA44 and SA43 was uptaken by 1321N1 cells and localised to the cytoplasm (arrows in A 
and D). Uptake SA56 RNA showed minimal uptake by the cells (G).  The no aptamer 
control aptamer also showed minimum fluorescence (I) and both SA neg 1 and SA neg 2 
showed reduced binding to 1321N1 cells (M and P).  Cells were counterstained with the 
nuclear dye DAPI (B, E, H, K, N, Q).  Images C, F, I, L, O and R showed merged Cy3 and 
DAPI images. Cells were viewed with a confocal microscope at 40x with an oil assisted 
lens. Scale bar = 20µm 
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Figure 4.2 shows images obtained using confocal microscopy Cy3 conjugated aptamers. 
Image a and d shows extensive uptake of the Cy3 labelled aptamer SA44 and SA43 DNA 
aptamer by the 1321N1 cell line, respectively. This is similar to U87MG cell line (Figure 
4.1). The binding appears to be in the nucleus as well as the cytoplasm and appears more 
intense (red arrows). The binding is different to U87MG cell line where a haloing of the 
Cy3 signal could be seen in the merged images (Figure 4.1, images c and f). The binding 
is likely on the surface membrane as well. Few cells show greater binding compared to 
others, again signifying a variation in uptake possibly due to the growth phase of the 
cell. Image g shows SA56 RNA aptamer binding which is very minimal. The no aptamer 
control (j) showed minimal binding. Reduced binding was detected with SANeg1 and 
SANeg2 aptamer compared to SA43 and SA44. SANeg1 and SANeg2 were random 
sequence aptamers generated as a control for the project. There was differential biding 
in the SANeg1 and SANeg2 aptamers when compared to SA43 and SA44 aptamers and 





Figure 4.3 Confocal imaging of live SVGp12 cells incubated with 100nM of Cy3 
conjugated aptamers.   
Minimal uptake of SA44, SA43 and SA56 RNA was detected in SVGp12 cells (A, D and G). 
More uptake was observed with SA43 (D) than SA44 (A) and SA56 RNA (G). The no 
aptamer control showed no fluorescent staining (J) and SANeg1 and SA neg 2 showed 
minimum uptake by the cells (M and P).  Cells were counterstained by the nuclear dye 
DAPI (B, E, H, K, N and Q). C, F, I, L, O, and F showed merged Cy3 and DAPI images.  SA44 
and SA43 appear to be localised in the cytoplasm and showed more intense binding when 
cells appeared be dividing (arrows C and F). Cells were viewed on a confocal microscope 
at 40x with an oil assisted lens. Scale bar =20µm 
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Figure 4.3 shows images obtained using confocal microscopy with fluorescent tagged 
aptamers. Image a and d show some uptake of the Cy3 labelled aptamer SA44 and SA43 
by SVGp12. The uptake of SA43 aptamer in image (d) is greater than that of SA44 in 
image a. The binding to SVGp12 cells is markedly reduced compared to U87MG (Figure 
4.1) and 1321N1 (Figure 4.2) cell lines. The aptamer binding appears to be present in the 
cytoplasm and minimally in the nucleus. This points to the fact that the nature of SVGp12 
cells is different when compared to U87MG and 1321N1 cell lines with respect to the 
binding affinity of the aptamer sequences used in the experiments. The binding is seen 
greater in cells which are present in pairs of two and could be in division or in mitosis 
(Wadsworth, 2007) (red arrows in figure 4.3, (c) and (f)). The increased binding seen in 
dividing cells signifies binding of aptamer to over expressed targets during mitosis and 
cell division. This signifies likely greater targeting of dividing cells by the aptamer.  No 
fluorescence can be seen in the control image (j) with no aptamer. Cy3 fluorescence can 
be seen in SAneg2 but not seen in SAneg1 except background non-specific staining. This, 
thus signifies aptamer binding to cells with SAneg2 but not with SAneg1. 
4.3 Biotin-tagged aptamer staining 
4.3.1 Biotin aptamer with commercial cell lines 
 U87MG, 1321N1 and SVGp12 cell lines showed consistent patterns of binding with Cy3 
tagged aptamer, mainly SA44 and SA43. SA56, the RNA aptamer did show some binding 
to U87MG (figure 4.1, g) but not in other cell lines and not as significant binding 
compared to SA44 and SA43 (figure 4.1, 4.2, and 4.3). SA56 was not used further due to 
inconsistent results on further replicates and not selective to glioma cell lines. Cell lines 
U87MG and 1321N1 showed greater binding compared to SVGp12 to all the aptamers. 
SVGp12 cells were therefore used as the control cell line.  SAneg1 and SAneg2 showed 
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some binding. SAneg1 appeared to bind to 1321N1 cell line but not to the other two cell 
lines and SAneg2 bound to U87MG more than SVGp12. SAneg1 and SAneg2 aptamers 
were utilised for further experiments since they were random novel aptamers. To 
enable aptamer target identification, the aptamers were tagged with biotin instead of 
Cy3 as biotin would be used in downstream precipitation experiments. The hypothesis 
was that replacement of Cy3 with biotin is not going to alter the binding structure of the 
aptamer (Ruigrok et al., 2012). This was initially attempted with live incubation with the 
biotin tagged aptamer (Chapter 2.8.1). Live incubation with biotinylated aptamer was 
not carried further as fixation of cells after incubation would cross link biotin as well, 
thus making detection of biotin difficult. Immunostaining techniques harbour the use of 
streptavidin-biotin affinity and endogenous biotin is blocked prior to DAB staining as 
standard to stop false positive result. The blocking of biotin would render the pre-
reacted biotin-aptamer unavailable for binding. Therefore, the cells were incubated with 
biotinylated aptamer after fixation and permeabilisation (Chapter 2.8.4, Figure 4.4). The 







Figure 4.4 Staining of fixed cell lines U87MG, 1321N1 and SVGp12 with 100nM SA44, 
SA43, SAneg1 and SAneg2 aptamer. 
SA44 showed binding to U87MG (A) and 1321N1 (B) cells but reduced binding to SVGp12 
(C) cells.  SA43 also showed binding to U87MG (D) and 1321N1 (E) cells and moderate 
levels of binding to SVGp12 (F) cells predominantly in the nucleus. SAneg1 showed some 
binding to all cell lines ((G, H and I) whereas SAneg2 showed minimal binding (J-L). As 





Figure 4.4 showed SA43 and SA44 staining to glioma cells lines U87MG and 1321N1 and 
the control SVGp12 cell line.  SA44 and SA43 bound to U87MG and 1321N1 cell lines as 
determined by the dark brown staining in the cytoplasm and around the nucleus (images 
a, b, d, e). SVGp12 also showed binding with SA44 and SA43 but mainly nuclear stain and 
not as strong as the glioma cell lines. There was minimal cytoplasmic staining in the 
SVGp12 cell lines (images c and f). Similarly, SAneg1 showed binding to U87MG and 
1321N1 in the nuclear and cytoplasmic regions but reduced binding around the nuclear 
region of SVGp12. This suggests that SAneg1 appears to be reacting, similar to SA44 and 
SA43 aptamers and conforms to being a positive control to the aptamer staining itself. 
SAneg2 aptamer showed reduced staining across all three commercial cell lines (images 
j, k and l). In light of SA44, SA43 and SAneg1 aptamers, SAneg2 will be used as the 
negative control aptamer in downstream experiments.  As expected, the control images 
(with no aptamer) do not show any staining (images m, n and o). SAneg2 images and 
control images show that the aptamer binding is selective to glioma cells.  
4.3.2 Biotin aptamer with short term culture 
In order to determine the translational potential of aptamers in the clinic, it was 
necessary to investigate aptamer binding to patient derived short term cultures.  IN1528 
and IN1612 were derived from grade IV glioma short term cultures created at the 
institute of neurology (Maleniak et al., 2001). The two short term cultures were 
characterised before use and confirmed as glial and human in origin. BTNW 914, BTNW 
911 and BTNW 370 were short term cultures from patient tissue generated from patient 
tissue at the Royal Preston Hospital, Preston, England. These three cell lines have been 




Figure 4.5 DAB staining of short term cultures IN 1528 and IN 1612  
IN 1528 and IN1612 with SA44, SA43, SAneg1 and SAneg2 aptamer with control (no 
aptamer). Aptamer at 100nm concentration. Scale bar represents 20 µm. SA44, SA43 
aptamer showed staining to cytoplasmic and nuclear regions to IN1612 (images b and 
d).  SAneg1 showed perinuclear staining (images e and f). The control images (with no 
aptamer) did not show any staining (images i and j). 
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In Figure 4.5, SA44 bound to glioma short term cultures IN1528 and IN1612, derived 
from patient tissue. SA43 showed binding to IN1612 but not to IN1528.  A 
heterogeneous pattern of binding was observed in the short term cultures than in the 
glioma cell lines, illustrating the heterogeneous nature of patient derived tissue and the 
selectivity of the aptamers to their target. SA44, SA43 aptamer showed strong staining 
to cytoplasmic and nuclear regions to IN1612 (images b and d). SAneg1 showed 
perinuclear staining (images e and f) and heterogeneous but much reduced compared 
to binding in cell lines (Figure 4.4). SAneg2 aptamer did not show any staining to the 
cells (images g and h) and is consistent with findings from the cell lines. The control 
images (with no aptamer) did not show any staining (images i and j). This confirmed the 
staining to be due to aptamer binding and specific. SAneg2 images and control images 
show that the aptamer binding is specific. As seen in fluorescent staining (Figure 4.1) 






Figure 4.6 DAB staining of short term cultures, BTNW  
 BTNW 914 BTNW 911 and BTNW 370 with SA44, SA43, SAneg1 and SAneg2 aptamer 
with control (no aptamer). Aptamer at 100nm concentration. Scale bar represents 20 
µm. SA44, SA43 aptamer bound to cytoplasmic and nuclear regions (images a, b, c, d, e 
and f). SAneg1 showed some staining (images g, h and i). SAneg2 aptamer did not show 
any staining to the cells (images j, k and l). The control images (with no aptamer) did not 
show any staining (images m, n and o). Hence the aptamer incubation is binding to cells 
and not non-specific. 
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In Figure 4.6, SA43 and SA44 bound to glioma short term cultures BTNW 914, BTNW 911 
and BTNW 370, derived from patient tissue.  A heterogeneous pattern of binding was 
observed in the short term cultures than in the glioma cell lines, and staining was 
markedly reduced in comparison to the cell lines, illustrating the heterogeneous nature 
of patient derived tissue and the selectivity of the aptamers to their target. SAneg1 
showed some staining (images g, h and i) with mainly cytoplasmic and perinuclear 
appearance. SAneg2 aptamer did not show any staining to the cells (images j, k and l) 
and is consistent with findings from the cell lines. The control images did not show any 
staining (images m, n and o). This confirmed the staining to be due to aptamer binding 
and specific. SAneg2 images and control images show that the aptamer binding is 
specific. 
4.4 Discussion 
The aim of the chapter was to confirm the binding of SA43 and SA44 aptamers to glioma 
cell lines and patient derived tissue. The aim was also to assess the selectivity of the 
aptamers by including a glial cell line, SVGp12 as a non-cancerous control.  The results 
show the SA43 and SA44 aptamers bound consistently and reproducibly to glioma cells, 
and that both Cy3 and biotin tagged aptamers can be utilised for targeting to glioma 
cells.  
Aptamers identified by Cerchia et al were shortened in length since the primer increases 
the length of the aptamer which may impact on penetration through the BBB (Pan and 
Clawson, 2009). Aptamer binds to its targets using various binding forces like van der 
Waals and hydrogen bonding (Patel, 1997), together to conform to specific targets. The 
longer the aptamer, the greater chances of it binding or being ‘sticky’ to multiple 
molecules and reducing specificity. As aptamers are single stranded DNA or RNA, they 
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are able to contort into different 2D and 3D structures (Feigon et al., 1996; Lin and Patei, 
1997; Patel, 1997). 2D structures are easier to predict using freely available online 
software such as M-Fold (Zuker, 2003). To reduce non-specificity, shorter aptamer 
sequences are better (Pan and Clawson, 2009). Since the active part of the aptamer is 
due to the conformation of the 3D structure, forming the ‘loop’ (Guo, 2010), the 
aptamer can be reduced in nucleotide number depending on what is hypothesised as 
the correct computational binding site (Cerchia et al., 2009; Nadal et al., 2013) . Further 
truncation can result in a more specific aptamer but can also affect the stability of the 
aptamer (Nadal et al., 2013). Aptamer folding was predicted using Mfold (Zuker, 2003) 
for the likely 2D structure and stem loop motifs typically observed in single stranded 
oligonucleotide folding. It was decided to utilise DNA aptamers in this research project 
due to improved stability compared to RNA aptamers, which may be of benefit for 
translation into clinical use if aptamers are utilised as novel therapeutics and/or drug 
targeting moieties (Zhu et al., 2015).  
The aptamers were produced using SELEX against U87MG cells. The primers were 
merely attached to expand the population of the aptamer sequences by replication and 
in theory should not affect the final targeting potential of the aptamer. In contrast, 
Cerchia et al showed that incubation of truncated GL43 -44 aptamer with U87MG 
showed a time dependent reduction in detection of cyclin D1 detection and ERK 
phosphorylation, whereas in our studies, there was no biological activity of either SA43 
or SA44 in U87MG cells (Aptekar et al., 2015) suggesting SA43 and SA44 DNA aptamers 
bind to a different target than the truncated RNA version.  
Live cell incubation at 37°C showed that the aptamer was taken up readily by the glioma 
cell lines U87MG and 1321N1 compared to SVGp12. The aptamer appears to be present 
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mainly in the cytoplasm and perinuclear region as per the confocal imaging. There was 
fluorescence was also detected (indicating aptamer binding) in SVGp12 cells but is 
markedly reduced compared to the glioma cell lines. This could be likely due to the 
presence of similar target in the cells lines but over detection in the glioma cell lines.  
Confocal imaging at various depths did show aptamer binding around the cell 
membrane. The variation in the signal intensity also suggests that the aptamer target 
ligand is likely present on the cell surface as well and may well be an over detection of a 
cytoplasmic or nuclear structure.  
The detection of aptamer binding to fixed cells was due to biotin-avidin interaction 
(Weber et al., 1989). Pre-incubation with the aptamer to live cells followed by cross-
linking (fixing) to stabilize the cells would have made the biotin unavailable for 
detection. Also, the blocking of endogenous cellular biotin would also block the biotin 
conjugated to the aptamer, thereby invalidate any available biotin sites for avidin 
binding. Thereby, endogenous biotin was blocked after cell fixation prior to cell 
permeation and incubation of the biotin-conjugated aptamers. The hypothesis adapted 
was that the aptamers should continue to bind their target ligand via the non-covalent 
forces between aptamer and target irrespective of whether Cy3 or biotin was used as 
the tag (Starikov and Nilsson, 2002). This is similar to actual antigen-antibody interaction 
utilised in immunocytochemistry and supporting the use of aptamers as a direct 
replacement for antibodies. Later, the cells were incubated with biotinylated aptamer 
after fixation and permeabilisation (chapter 2.8.4) and showed consistent results of 
greater staining on the cancerous cell lines compared to SVGp12.  Staining was found 
across the cellular matrix in the tumour cell lines whereas SVGp12 cell line showed faint, 
mainly peri-nuclear staining.  No staining was seen in the control used with no aptamer. 
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Aptamer staining with both Cy3 and biotin showed binding in the cytoplasm and 
nuclear/peri-nuclear region. It was evidently seen more in the glioma cell lines 
compared to SVGp12. The binding appeared to be heterogeneous across the cells 
(Wadsworth, 2007). This could be because of varying detection of target molecule at 
various stages of the cell cycle.  
Aptamer staining was then replicated to short term cultures. Gliomas, by nature, are a 
group of heterogeneous tumours and targeting is difficult due to the heterogeneity 
(Soeda et al., 2015). It was hence important to see the binding of the aptamers in patient 
tissue derived short-term cultures and assess the specificity. Significant binding of the 
SA43 and SA44 aptamers was also detected in the short-term cultures, but with greater 
heterogeneity than commercial glioma cell lines (compare Figure 4.6 with Figure 4.4).  
Two control aptamers, SAneg1 and SAneg2, which were of equivalent composition to 
the SA43 and SA44 aptamers randomly generated were used as a control aptamers. 
Biotin tagged SAneg1 bound to the commercial cell lines and short-term cultures but no 
binding was detected with SAneg2. This was replicable across the cell lines and further 
confirmed the fact that the binding of SA43 and SA44 appeared to be specific, towards 
a target rather than being pure DNA affinity. A parallel study looked at the application 
of these aptamers towards tissue diagnosis (Aptekar et al., 2015). The study showed that 
SAneg1 appeared to bind to majority of tissue sections including normal tissue whereas 
SAneg2 only bound to very few tissue sections. The binding properties could be used as 
a positive control with SAneg1 (not necessarily the relevant target) and negative control 
for SAneg2, hence their use in further experiments.  
As a result of the experiments in this chapter, we were able to confirm consistent Cy3-
aptamer staining to glioma cells. This was reproduced with biotin-conjugated SA43 and 
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SA44 aptamers thus proving that biotin is not interfering with the aptamer binding. The 
results were reproducible using short-term cultures, which are an important part of 
target detection, being patient derived. The aim of the project is to be able to apply the 
techniques towards patient specific targeted treatment and short-term cultures are a 
relevant step in the process. Presence of a negative (SAneg2) and possible positive 
control (SAneg1) proved the hypothesis of the current experiment and supported the 
next stages of research. Further pull-down and elution of the targets would throw more 
light on the nature of target proteins for the different aptamers in chapter 5 and chapter 
6. 
The next chapter details the protein extraction methodology and aptamer assisted 
precipitation of the target protein and its identification using mass spectroscopy. To 
identify the target, optimal protein extraction is essential. Since the aptamer binds to 
the target, the intention was to crosslink the aptamer to its target to maintain the 
binding during the target precipitation. The precipitate would then be identified using 
mass spectrometry and compared against known proteomic databases to identify and 








Chapter 5  
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5 Optimisation of protein extraction, aptoprecipitation and 
proteomic analysis 
5.1 Introduction 
Conventional 3,3-Diaminobenzidine (DAB) staining and confocal imaging confirmed the 
selective uptake of SA43 and SA44 by U87MG and 1321N1 cell lines.  It is not known, 
however, the identity of the target ligand to which the aptamers bind.  In order to 
identify their respective targets, protein extraction and quantification experiments were 
carried out. Chromatin immunoprecipitation, or ChIP, uses streptavidin-biotin 
interaction to pulldown the antibody target ligand which can then be identified by mass 
spectrometry. ChIP methodology was adapted to use aptamer target interactions rather 
than antibody based interactions. 
Optimal protein extraction is essential to confirm the binding targets. Harsh conditions 
for protein extractions, chemically or with heat can denature the epitope being 
investigated thereby compromising the ability to interpret the data obtained.  
Two approaches for protein extraction from cultured cells were assessed using unfixed 
cells and fixed cells. Protein extraction using unfixed cells is well published with various 
existing techniques such as chemical (detergent) or mechanical (pestle and mortar) (Cilia 
et al., 2009; Lee, 2017).  Protein extraction from fixed cells involved incubation of live 
cells with the aptamer followed by fixation using PFA, however has not been published 
before, so this was a novel approach to be tested. The concept being tested was to 
determine if crosslinking of the epitope to the aptamer resulted in the maintenance of 
the aptamer–target interaction. Protein extraction from fixed tissue as published utilises 
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heat and TCA extraction (Sadick et al., 2016; Sadick and Darling, 2017) but application 
with pre-reacted aptamer and effect on aptamer target binding is unknown. 
Based on the results of Chapter 4, it was hypothesised that active aptamer uptake 
happens during live cell incubation, based on Cy3 staining (chapter 4.2). DAB staining 
with biotinylated aptamer showed consistent binding results and availability of target to 
aptamer despite cross linkage (chapter 4.3). Hence, the proof of concept was carried 
further and incubation with both live and fixed cells was performed with attempted 
protein extraction. Cells were fixed using 4% PFA and subjected to various lysis methods 
to achieve a target protein concentration of 2mg/ml for pulldown experiments. Protein 
was quantified using Bradford assay (Bradford, 1976; Ernst and Zor, 2010). 
Unfixed cells were used for optimisation of protein quantification method using 
Bradford assay as a baseline. With live cells, there remained a concern of exposing the 
intracellular components to the aptamer on lysis. This might expose targets which the 
aptamer would not necessarily have access to in cells in their native form, and thus may 
generate false positive results. 
Once adequate protein extraction was achieved, cells were subjected to aptamer 
incubation and streptavidin coated beads were used for protein pulldown assay, utilising 
streptavidin-biotin affinity for pull-down of targets. 
Various buffers were used for protein interaction to keep aptamer epitope interaction 
as close to normal cellular physiology as possible (for example physiological buffered 
salts and physiological pH 7.4) and to reduce protein degradation. The protein extracted 
was compared to other techniques of protein extraction to confirm the optimal protein 
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content and quality of protein extraction. After developing the protocol, novel aptamers 
raised against glioma cell lines were used to verify the pulldown technique.  
The epitopes were then identified by mass spectrometry analysis and target 
identification was confirmed by Western blot and siRNA in Chapter 6. 
5.2 Protein extraction - 
The results of the protein extraction method development are represented in the 
flowchart in Figure 5.1. Fixed and unfixed cells were used for the protein extraction and 
multiple buffers were tested for efficient extraction and compared using Bradford assay. 
Fixed cells, pre-reacted with the aptamer were used to crosslink the target to the 
aptamer. This would enable reduction in non-specific pulldown and also reduce the loss 
of the target during the downstream process of extraction. Unfixed cells were initially 
used to establish the protein extraction techniques and for protein gel electrophoresis. 
The unfixed cells became the important component of the project due to the difficulties 
face in protein extraction from fixed cells as detailed in the chapter. Due to the 
complexity of the optimal protein extraction technique, it is represented in a flowchart. 
The flowchart and the various combinations of reagents used in the development of the 
process are detailed in the next section and images. We will refer to the flowchart and 
justify how the final protein extraction protocol was optimised using various sections 




Figure 5.1 The process of protein extraction method development with cells.  
Fixed and unfixed cell were used for protein extraction. After cell culture cells, were either 
incubated with aptamer or kept for lysis and incubation with aptamer (side arm). Cells 
which are pre-incubated with aptamer were either fixed or kept unfixed. Fixed cells, pre-
incubated with aptamer were either placed directly into cell lysis buffers or subjected to 
mechanical, freeze-thaw and sonication methods for cell lysis before placing into lysis 
buffer(s). Unfixed cells were subjected to lysis by standard lysis buffers after aptamer 
incubation. Unfixed cells were then lysed first (side arm of the flowchart) and later 




5.2.1 Protein extraction using fixed cells 
Cells were first incubated with aptamer according to previous chapters and then fixed 
using PFA to be able to pull down the aptamer target epitope. Our collaborative research 
(Aptekar et al., 2015) has shown that the affinity of the aptamer for the target ligand is 
in the nM range with both SA43 and SA44 exhibiting dissociation constants (Kd) at 21.56 
± 4.6 nM and 21.11 ± 3.3 nM, respectively. Although our previous data showed the 
aptamers have high affinity for the target ligand, it is important to minimise disruption 
of the target-ligand interaction during the protein extraction stage.  Cells were fixed 
using 4% PFA as in chapter 2.9.1. Post fixation, the cells were lysed using RIPA lysis 
buffer, RIPA lysis buffer with 2% SDS (sodium dodecyl sulphate) lysis buffer, 2% SDS lysis 
buffer, 1% lysis buffer and native lysis buffer (Figure 5.2). The protein extraction was 
tested using Bradford assay, by comparison of sample absorbance to absorbance of 
known BSA standards (Figure 5.3).  
 
Figure 5.2 Fixed cell stage from protein extraction method development 
Various lysis buffers as depicted in flowchart were used for protein extraction from fixed 





Figure 5.3 Typical standard curve for Bradford assay  
Bradford assay showing absorbance of bovine serum albumin (BSA) standards run used 
for determination of protein concentration in extraction samples (n=3 repeats). Note the 
standard curve was performed at every experiement.  
Fixed cell lysis with lysis buffers alone showed poor protein extraction with visible cell 
pellet left after lysis. Fixed cell lysis is difficult due to PFA cross-linkage in cell matrix 
(Ikeda et al., 1998; Sadick et al., 2016) and may require treatment with heat, chemical 
or physical measures.  
5.2.2 Fixed cell protein extraction using mechanical methods  
The fixed cells as described in section 2.9.1 were then subjected to protein extraction 
using mechanical methods (Figure 5.4). For uniformity of experiments, RIPA lysis buffer 
was used for other treatment methods of fixed cells as no difference was seen in the 
protein content extracted from other lysis buffer as in chapter 5.2.1 and RIPA has the 




Figure 5.4 Mechanical methods for protein extraction from fixed U87MG. 
Fixed U87MG cells were incubated with 100nm aptamer then fixed with 4% PFA. Fixed 
cells were then subjected to lysis using agitation of cells with glass beads in an Eppendorf 
tube. Alternatively, cells were lysed by aspiration with a syringe and 27g needle. 
Cells were fixed and suspended in RIPA lysis buffer. They were then subjected to lysis 
using glass beads and 27G syringe methods (Thermofischerscientific, 2010). The proteins 
extracted were then run on gel electrophoresis as imaged in figure 5.8 along with other 
lysate methods, to compare protein content and quality. 
 
5.2.3 Fixed cell protein extraction using thermal methods  
The fixed cells as described in section 2.9.1 were then subjected to protein extraction 
using heat and freeze thaw cycles as different methods (Thermofischerscientific, 2010) 
and as detailed in chapter 2.9.1 (Figure 5.5). Protein was extracted from fixed U87MG 
cells after subjecting the cell pellets to heat at 95⁰C for 2 hours. The proteins extracted 
were then run on gel as imaged in figure 5.6. Quality of protein content was considered 





Figure 5.5 Thermal lysis methods on fixed U87MG cells.  
U87MG cells were incubated with 100nM aptamer, fixed with 4%PFA then subjected to 
8 freeze thaw cycles or heat suspension at 100˚C.   
 
Figure 5.6 Heat extracted protein from fixed cells.  
Protein lysate after thermal extraction from fixed U87MG cells. Distinct protein bands 
wer edetected which suggests high quality protein was extracted. 
5.2.4 Fixed cell protein extraction using sonication methods  
The fixed cells as created in chapter 2.9.1 were then subjected to protein extraction 
using bath sonication and probe sonication as different methods 
(Thermofischerscientific, 2010) and as detailed in chapter 2.9.1 (Figure 5.7). Visible 
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inspection of the cell pellet did not show any disintegration, and therefore this method 
was not processed further for Bradford assay or for polyacrylamide gel electrophoresis.  
 
Figure 5.7 Bath and probe sonication on fixed U87MG cells.  
U87MG cells were incubated with 100nM aptamer, fixed with 4% PFA and subjected to 
bath or probe sonification. 
When using fixed cells, proteins were diluted 10x for Bradford assay, (figure 5.3), giving 
an average protein concentration of 400 – 500 µg/ml. This was seen across other 
methods with fixed cells. The proteins extracted were then run on a 10% polyacrlamide 
gel (figure 5.8) along with other lysate methods. Quality of protein was considered 





Figure 5.8 U87MG cells fixed with 4% PFA and subjected to various mechanical 
methods for protein extraction.  
Lane 1 shows protein extraction using 0.1% SDS RIPA lysis buffer after freeze thaw cycles 
and appears to have the maximal concentration of protein compared to other lanes. 
Lane 2 is protein extraction using 2% SDS with RIPA lysis buffer, subjected to freeze thaw 
cycles. Lane 3 is 2% SDS only lysis buffer subjected to freeze thaw cycles. Lane 4 is RIPA 
lysis buffer with mechanical syringing of cells. Lane 5 and 6 are glass bead lysis in RIPA 
buffer and native lysis buffer respectively. 
5.2.5 Unfixed cell protein extraction  
U87MG cells were trysinised as in chapter 2.9.3 and lysed using RIPA lysis buffer and 
0.1% Triton X100 lysis buffer as in figure 5.9. RIPA was used as it is a standard lysis buffer 
used in proteomics. RIPA is knonnw to be a good buffer for nuclear protein extraction. 
It does though denature the protein.  Triton X100 does not denature the protein and is 




Figure 5.9 Buffer lysis of U87MG cells. U87MG cells were lysed with either RIPA lysis 
buffer or Triton x100 lysis buffer.  
Bradford assay was performed for the cell lysates for various cell lines and table 5.1 
details the results of protein extracted. 
Table 5-1 Protein concentration extracted from unfixed U87MG cells n=3 
 
Unfixed Cells Protein concentration 
(Milligram of protein per 
ml of lysate) 
U87MG  3.6 
1321N1  5.35 
SVGp12  4.21 
 
Unfixed cells showed better protein extraction when compared to fixed cells. The 
extracted protein cell pellet also displayed visual clarity with no residual clumped sample 
in the Eppendorf tubes after lysis when compared to fixed cell lysis. Unfixed cells were 
lysed with RIPA and triton X100 as two steps of the flow chart as shown in Figure 5.9. 
Equivalent protein extraction was achieved from each as displayed above. The extracts 
from unfixed and fixed cells were also run on a gel to assess for quality of protein 
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separation (figure 5.10). There was cleaner appearance of bands on the unfixed protein 
separation lanes, pointing to better quality protein.  
 
Figure 5.10 Protein extracts from unfixed and fixed U87MG cells 
Distinct bands can be seen in the unfixed cell lysates compared to fixed cells (heat 
extracted) appeared with clear demarcation and greater in number. The gels are from 
the cell lysates and had equal loading protein content of 2.5mg/ml. 
Final extraction protocol was utilised with triton X100 as it does not denature the protein 
and allows it to be reacted in its native form. The aptamer incubation in the unfixed cells 
would happen after lysis and it did raise the question of non-specific binding. In chapter 
3 and chapter 4, clear internalisation of the aptamer was seen and supported binding 
likely on the surface as internalisation appeared to be an active process (Aptekar et al., 
2015). Pre-reacting the aptamer to live cells and fixing, cross links the biotin attached to 
the aptamer as shown in chapter 4. Reversing this linkage with heat as in section 5.2.3 
does give good protein content but aptamer-biotin link and target binding of the 
aptamer are not detected. Thus, aptamer incubation with unfixed cell lysate with triton 
X100 was adapted for assisted pull-down technique as in chapter 5.3.  
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5.3 Aptamer assisted pulldown of proteins 
5.3.1 Method development 
Chromatin immunoprecipitation or ChIP is a well established technique for biomarker 
discovery using antigen-antibody interaction (Aparicio et al., 2004; Viens et al., 2004). It 
employs the native attraction of streptavidin to biotin to enable the pulldown of target 
protein (Lee et al., 2006). Cell lysates with the target epitope or antigen are lysed after 
cross linking to pulldown the associated epitopes with the target antigen. The lysate is 
then incubated with biotin tagged antibody and then separated with column or beads 
(Dahl and Collas, 2008). The aim of the methodology is to extract the specific antigen 
and assess its expression in the lysate. ChiP protocol as per description was utilised as a 
guidance for the development of the aptamer assisted pull down.  
After optimisation of protein extraction (section 5.2), cell lysates were incubated with 
biotin tagged aptamers and pulldown was attempted. Cells were lysed at 4⁰C on a 
rotating platform, centrifuged and then incubated with the aptamer at the same 
temperature (chapter 2.11.4). Aptamer assisted precipitation was performed with the 
techniques as described in section 2.11.4.  
Initially, magnetic streptavidin beads were used for extraction of pulldown. Gel 
electrophoresis of extraction, shown in figure 5.11, shows good pulldown of protein with 
magnetic beads from lysate but there were multiple protein bands pulled down with the 
magnetic beads indicating non-specific cross reactivity with the aptamer and/or 





Figure 5.11 U87MG and 1321N1 cell lysate with aptamer assisted precipitation using 
SA43 aptamer. 
U87MG SA43 AP and 1321N1 SA43 AP showing multiple bands of lower intensity 
compared to input lysates (all cell lysate) respectively. There is no specific pull-down of 
protein detected.  The multiple bands in the AP lanes (aptamer assisted protein 
pulldown) suggest non-specific interaction with the aptamer and/or magnetic beads. 
The multiple bands detected in the protein pulldown in the input (all cell lysate) and AP 
(just the aptamer bound protein) is likely due to non-specific binding. In addition, visual 
inspection showed that the protein and magnetic beads had clumped and therefore 
seemed to be promoting non-specific protein binding. Hence, streptavidin-agarose 
beads were then tested to assess whether they were superior to magnetic beads in 
reducing non-specific protein interaction. Multiple washing steps were included as in 




5.3.2 Aptamer assisted pull-down of targets - results 
5.3.2.1 Cell line results 
U87MG, 1321N1 and SVGp12 cell lines were lysed and incubated with the aptamers 
SA43 and SA44. The resultant aptoprecipitation results are shown in Figures 5.12-5.14.  
 
Figure 5.12 U87MG cell lysate with aptamer assisted precipitation using SA44 and 
SA43 aptamers.  
U87MG cells were lysed and reacted with the aptamers SA44 and SA43 at 4⁰C. The 
reacted lysate was then incubated with streptavidin beads at 4⁰C and then washed for 
non-specific binding. The lysate bound to streptavidin beads was then eluted using 
laemmli buffer and run on 10% polyacrylamide gels and stained with Coomassie blue 
stain. These were then imaged using Geldoc™ imager (Bio-rad Laboratories Inc., 
Watford, UK) ™ imager (Bio-rad Laboratories Inc., Watford, UK) and showed specific 
bands in the SA44 AP and SA43 AP columns. The control AP is without aptamer and 





Figure 5.13 1321N1 cell lysate with aptamer assisted precipitation using SA44 and 
SA43 aptamers.  
1321N1 cells were lysed and reacted with the aptamers SA44 and SA43 at 4⁰C. The 
reacted lysate was then incubated with streptavidin beads at 4⁰C and then washed for 
non-specific binding. The lysate bound to streptavidin beads was then eluted using 
laemmli buffer and run on 10% polyacrylamide gels and stained with Coomassie blue 
stain. These were then imaged using Geldoc™ imager (Bio-rad Laboratories Inc., 
Watford, UK) ™ imager (Bio-rad Laboratories Inc., Watford, UK) and showed specific 
bands in the SA44 AP and SA43 AP columns. The control AP is without aptamer and 





Figure 5.14 SVGp12 cell lysate with aptamer assisted precipitation using SA44 and 
SA43 aptamers.  
SVGp12 cells were lysed and reacted with the aptamers SA44 and SA43 at 4⁰C. The 
reacted lysate was then incubated with streptavidin beads at 4⁰C and then washed for 
non-specific binding. The lysate bound to streptavidin beads was then eluted using 
laemmli buffer and run on 10% polyacrylamide gels and stained with Coomassie blue 
stain. These were then imaged using Geldoc™ imager (Bio-rad Laboratories Inc., 
Watford, UK) ™ imager (Bio-rad Laboratories Inc., Watford, UK) and showed specific 
bands in the SA44 AP and SA43 AP columns. The control AP is without aptamer and 
confirms absence of background binding to streptavidin beads. The image represents 
n=3 
Consistent pull-down results were seen with all three cell lines U87MG, 1321N1 and 
SVGp12. The pulldowns were performed three times and further assessed using mass 
spectrometry analysis in section 5.4. The optimised method was then applied to short 
term cultures to assess the robustness of the protocol and confirm similarity in patient 
derived short term cultures. 
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5.3.2.2 Short term culture results 
After the results of cell lines, short term cultures were expanded to enable experiments 
with optimal protein extraction and pull-down. Initial application was done with BTNW 
911 and BTNW 914 short term cultures.   
 
Figure 5.15 Short term culture BTNW 911 cell lysate reacted with SA43 aptamer.  
SA43 AP is the protein sample eluted with apto-precipitation and run on gel. Faint bands 
can be seen in the SA43 AP lane, marked by the orange arrows. The control lane is clean 
which is the sample eluted off cell lysate reaction alone with streptavidin beads, hence 
no non-specific pulldown. Due to the nature of short term cultures, further repeats could 




Figure 5.16 Short term culture BTNW 914 cell lysate reacted with SA43 aptamer.  
SA43 input is the gel band for the cell lysate alone. SA43 AP is the protein sample eluted 
with apto-precipitation and run on gel. Faint bands can be seen in the SA43 AP lane, 
marked by the orange arrows. The control lane is clean which is the sample eluted off 
cell lysate reaction alone with streptavidin beads, hence no non-specific pulldown. The 
SA43 AP bands were seen in two experiments with the cell line. Due to the nature of short 
term cultures, further repeats could not be carried out. This supports that the aptamer is 





Figure 5.17 Short term culture W2045 (A) and W859 (B) cell lysate reacted with SA43 
and SA44 aptamer. 
 SA43 AP and SA44 AP are the protein samples eluted with apto-precipitation and run on 
gel. Higher intensity bands was detected in the SA43 AP and SA44 AP lane. The control 
lane is clean which is the sample eluted off cell lysate reaction alone with streptavidin 
beads, hence no non-specific pulldown. The control lane is clean and no non-specific 
binding was detected. Due to the nature of short term cultures, single pull-down with the 
W2045 and W859 cell lines was done after optimisation of technique with commercial 
cell lines.  
5.3.3 Novel aptamer assisted pull-down of proteins and structural 
comparison 
The protocol developed using cell lines, for aptamer assisted pull down of proteins was 
applied to short term cultures, derived from glial tissue. This was seen in the section 
above and helped confirm the validity of the protocol and the aptamer interaction with 
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glial derived cell cultures. Further robustness of the protocol was planned with the use 
of novel aptamers generated in house at Uclan.  
5.3.3.1 Novel TDM aptamer assisted pulldown with cell lines and short term cultures 
A parallel project (Aptekar et al., 2015)looked at replication of aptamer generation using 
SELEX towards U87MG cell line as per Cerchia et al (Cerchia et al., 2009). Novel aptamers 
generated by SELEX were then used for DAB staining towards U87MG. Five of the 
aptamers generated showed good binding results in U87MG cell lines in a parallel 
project(Manangazira, 2013). Novel aptamers TDM2, TDM3, TDM7, TDM9 and TDM10 
were used for pulldown of proteins with cell lysates and short term cultures. The images 
in Figures 5.18-5.20 show the pulldown results. 
 
Figure 5.18 Aptamer assisted pulldown using SA and TDM aptamers with U87MG cell 
line. 
 Bands in the pulldown were detected in similar size range in SA43, TDM2, TDM3, TDM7 
and TDM10. SANeg1 lane shows bands which are multiple in number and appear 
different to the other aptamer AP lanes. The control lane (no aptamer) was clear and 




Figure 5.19 Aptamer assisted pulldown using SA and TDM aptamers with 1321N1 cell 
line.  
Bands in the pulldown can be seen in similar range in SA43, TDM2, TDM3, TDM7 and 
TDM10. SANeg1 lane shows bands which are multiple in number and appear different to 
the other aptamer AP lane. The control lane (no aptamer) is clear and confirms no non-
specific binding.  
 
Figure 5.20 Aptamer assisted pulldown using SA and TDM aptamers with W2045 cell 
line.  
Bands in the pulldown can be seen in similar range in SA43, TDM2, TDM3, TDM7 and 
TDM10. SANeg1 lane shows bands which are multiple in number and appear different to 
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the other aptamer AP lane. TDM9 shows faint bands. The control lane (no aptamer) is 
clear and confirms no non-specific binding. 
 
Figure 5.21 Aptamer assisted pulldown using SA and TDM aptamers with W859 cell 
line.  
Bands in the pulldown) can be seen in similar range in SA43, TDM2, TDM3, TDM7 and 
TDM10. SANeg1 lane shows bands which are multiple in number and appear different to 
the other aptamer AP columns. TDM 9 shows faint bands but stronger presence 
compared to W2045. The control lane (no aptamer) is clear and confirms no non-specific 
binding. 
The novel aptamer pulldown showed consistent bands seen between 60-100KDa and 
similar to pulldown with SA43 and SA44. There appeared to be less binding seen in TDM9 
and TDM10 in the pulldowns as imaged. This was seen consistently across all the glial 
cell lines and short term cultures.  
5.3.3.2 Aptamer computed structures using Mfold 
Mfold (Zuker, 2003), a DNA and RNA folding web server was used to compare the 
structures of the SA aptamers and also the TDM aptamers used in the pulldown analysis 
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(Figures 5.22-5.30). Since the aptamers are single stranded DNA, they fold to form 
secondary structures and ‘loops’. If a structure has greater number of predicted 
secondary structure, it is likely to be less specific. Though the final binding is due to a 
combination of hydrogen bonding and van der waals forces, the ‘loop’ in an aptamer is 
said to affect its affinity to binding targets (Feigon et al., 1996). 3D structure prediction 
of aptamers is also available in the form of SIMrna software and primarily predicting 
RNA structures (Genesilico, 2019). 
 
Figure 5.22 SA43 Mfold predicted structures 
Five structures of the SA43 aptamer are predicted using Mfold software. The various 
predictions have differing dissociation and stability but not dissimilar to each other. The 
multiple structures does increase the chance of the aptamer being able to bind to various 
targets and not to one alone. Though the structures are 2D, the final 3D structure is what 
gives the aptamer ability to bind and target. Further analysis of the aptamer structure 




Figure 5.23 SA44 Mfold predicted structures 
 SA44 has two predicted 2D structures on mfold. Repeats of ‘T-A-G-C-C-T’ is seen in the 
loop part of the aptamer. This repeat is similar to two of the structures seen in the SA43 
aptamer (figure 5.22 and figure 5.24 A and B). The loops are similar with similar repeats 
and hence the increased chances of binding to the same targets. SA44 though has only 
two predicted structures and the chances of the aptamer being more specific are higher. 
Despite the single nucleotide increase in the SA44 aptamer, both appear to bind to the 
same targets as per the protein gel electrophoresis. Final confirmation with the western 




Figure 5.24  Comparison of aptamer structure e in SA43 (A) and SA44 (B) 
‘T-A-G-C-C-T’ repeats seen in both SA43 (A) and SA44 (B) aptamer structures. The 




Figure 5.25 SANeg1 Mfold predicted structures  
SANeg1 which was made inhouse has three predicted 2D structures, each with a single 
stem loop. The loops are not similar to the SA43 or SA44 aptamers. 
 
Figure 5.26 SANeg2 Mfold predicted structures 
 SANeg2 shows a single structure as predicted by Mfold consisting of a single stem loop. 
Due to the presence of a single structure, the aptamer is likely to be more specific to its 




Figure 5.27 TDM2 Mfold predicted structures 
 TDM2, shows a single predicted structure on Mfold consisting of two stem loop 
structures. Due to the presence of a single structure, the aptamer is likely to be more 
specific to its target. The sequence does not share loops from SA43 or SA44. 
 
Figure 5.28 TDM3 Mfold predicted structures 
 TDM3 shows a single predicted structure on Mfold consisting of two stem loop 
structures. Due to the presence of a single structure, the aptamer is likely to be more 





Figure 5.29 TDM7 Mfold predicted structures 
 TDM7 shows a single predicted structure on Mfold consisting of two stem loop 
structures. Due to the presence of a single structure, the aptamer is likely to be more 
specific to its target. The sequence does not share loops from SA43 or SA44. 
 
 
Figure 5.30 TDM9 Mfold predicted structures 
 TDM9 has three different predicted structures. The structures appear more complex 
with multiple loops present in each structure. The aptamer due to the various loops is 





Figure 5.31 TDM10 Mfold predicted structures 
 TDM10 has two different predicted structures and each structure consists of two stem 
loops. The aptamer due to the various structures is likely to bind to different targets. The 
loops do not share nucleotide sequence with SA43 or SA44. 
 
5.3.3.3 Structural comparison of aptamers 
Common sequence in the loop structures is identified in the SA43 and SA44 aptamers as 
seen in figures 5.22, 5.23 and 5.24. The structures are predicted by Mfold based on ionic 
environment and temperature of folding. Typically, this is used for predicting RNA 
structures for mRNA binding. Binding is often associated with ‘stem’ and ‘loop’ 
structures, exposing critical sequences responsible for binding (Hofacker et al., 2002; 
Hofacker, 2004). When looking for the confirmation of the structure, it is likely one of 
the species is binding the target. This could be deduced by removal of bases and after 
loss for critical binding regions (Pan and Clawson, 2009) and described by ‘crawling’ 
method (Gopinath et al., 2017). The aptamer sequence is shortened to look for 
structural changes and when unchanged structurally can be used to look for similar 
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binding to target. In our research, the SA43 and SA44 aptamer showed similar sequences 
but the novel TDM aptamers had different stem and loops, thus implying the difficulty 
in predicting the final responsible sequence for target specificity. Since an aptamer binds 
with various binding affinities as detailed in section 1.5, the final target could be bound 
by multiple aptamers with different sequences but contain similar stem loop structures 
available for binding.  Mathematical simulation of SELEX (Irvine et al., 1991; Levine and 
Nilsen-Hamilton, 2007) and the mathematical complexity of predicting aptamers 
towards multiple targets (Vant-Hull et al., 1998) does not take into account the 
stochastic effects of SELEX. It has also been shown that multiple target SELEX is likely not 
as useful as single target SELEX (Seo et al., 2010). 
 
5.4 Proteomic analysis of pulldown proteins 
Aptamer assisted pulldown of proteins from cell lines were sent for mass spectrometry 
proteomic analysis. The methodology was refined to ensure that aptamer bound 
proteins eluted from the streptavidin- agarose beads separated by gel electrophoresis 
were only present in the eluent (determined by corresponding clear lanes in the control 
gels). Initially, every protein band in the lane from the gel electrophoresis separation of 
aptamer assisted pulldown were excised and sent for proteomic analysis to identify the 
proteins. At later stages, only the consistent and most prominent bands were sent for 
replication of proteomic analysis to confirm results.  Densitometry analysis of the 
aptamer pulldown was done on Geldoc™ imager (Bio-rad Laboratories Inc., Watford, UK) 
™ imager (Bio-rad Laboratories Inc., Watford, UK) software with identified gel bands in 
the pulldown lanes. Mass spectrometry analysis of all the gel bands and blocks was 
performed at St Andrews University, Dundee. 
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5.4.1 Full proteomic analysis of aptamer assisted pulldown with SA43 
aptamer in U87MG and 1321N1 cell lines 
5.4.1.1 Pulldown from U87MG 
Aptamer assisted pulldown with U87MG and 1321N1 cell lines were run on 10% 
polyacrylamide gels. These were then stained with Coomassie blue stain and imaged 
using Geldoc™ imager (Bio-rad Laboratories Inc., Watford, UK) ™ imager (Bio-rad 
Laboratories Inc., Watford, UK)™ imager (Bio-rad Laboratories Inc., Watford, UK) (figure 
5.32).  
  
Figure 5.32 Aptamer assisted pulldown with SA44 and SA43 aptamers with U87MG 
cells.   
The input lane shows the protein analysis of the cell lysate loaded onto the streptavidin-
agarose beads, whereas the AP lane shows the protein analysis of eluent after aptamer 
assisted precipitation (AP). The two gel images are same and the second image on the 
right points to the specific identified bands and blocks sent for mass spectrometry. The 
control lane shows the same cell lysate that was loaded onto the agarose beads, but 
without any aptamers conjugated. The prominent bands and lane blocks, as indicated by 
red boxes, were sent for mass spectroscopy based proteomic analysis.  
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The aptamer pull-down columns were separated into segments and excised from the 
gels using sterile blades for each segment. The images in Figure 5.32 shows aptamer 
assisted pull-down of proteins in U87MG cell lines, using the SA43 and SA44 aptamers. 
Gel samples were prepared and digested with trypsin and peptides were analysed by 
LC-MS/MS mass spectrometry analysis (figure 5.33).  
 
Figure 5.33 Densitometry and mass spectrometry analysis 
Densitometry analysis of the SA44 and SA43 pulldown on Geldoc™ imager (Bio-rad 
Laboratories Inc., Watford, UK) ™ imager (Bio-rad Laboratories Inc., Watford, UK) 
software with identified gel bands in the pulldown lanes. Mass spectrometry analysis of 
the gel bands and the top 5 significant proteins hits for SA43 aptamer with U87MG cell 
line, performed at St Andrews University, Dundee. The terms in blue are all proteins with 
binding function. X-ray cross complementing (XRCC) protein 5 is Ku80 and Poly-(ADP-





Figure 5.34 Protein analysis from SA43 aptamer and U87MG cell line.  
Proteomic analysis from SA43 aptamer showed over a quarter of the binding is with 
nucleic acid binding proteins (orange sector) along with presence of cytoskeletal 
structure protein, transporters and transfer proteins amongst other hits. 
The proteins were identified using Mascot software from matrix science with at least 2 
peptides with 95% confidence and analysed using Panther protein classification 
software. The top five most abundant proteins identified for each gel fragment are 
shown in figure 5.33 with Panther analysis results (figure 5.34). Nucleic acid binding 
proteins were found to be in the highest content in the analysis (figure 5.34).  
5.4.1.2 Pulldown from 1321N1 
1321N1 cell line was also sent for mass spectroscopy analysis and the results were 
shown in Figures 5.35 for gel electrophoresis, Figure 5.36 for band excision and top five 
proteins identified and Figure 5.37 for Panther analysis. The sample were processed with 




Figure 5.35 Aptamer assisted pulldown with SA44 and SA43 aptamers with 1321N1 
cells. 
The input lane shows the protein analysis of the cell lysate loaded onto the streptavidin-
agarose beads, whereas the AP lane shows the protein analysis of eluent after aptamer 
assisted precipitation (AP) using SA43 and SA44 aptamer. The two gel images are same 
and the second image on the right points to the specific identified bands and blocks sent 
for mass spectrometry. The control lane shows the same cell lysate that was loaded onto 
the agarose beads, but without any aptamers conjugated. The prominent bands and lane 
blocks, as indicated by red boxes, were sent for mass spectroscopy based on Geldoc™ 
imager (Bio-rad Laboratories Inc., Watford, UK) ™ imager. The results of the mass 




Figure 5.36  Densitometry analysis of SA43with 1321N1 cell line 
SA43 and SA44 pulldown on Geldoc™ imager (Bio-rad Laboratories Inc., Watford, UK) ™ 
imager (Bio-rad Laboratories Inc., Watford, UK) software with identified gel bands in the 
pulldown lanes. Mass spectrometry analysis of the gel bands and the top 5 significant 
proteins hits for SA43 aptamer with 1321N1 cell line. The terms in blue are all proteins 
with binding function. XRCC 5 and XRCC 6 (Ku80 and ku70 respectively) and PARP were 
the significant hits in the pulldown as seen in the image above. Replication protein A was 
also seen along with nucleolin. Figure 5.37 shows the breakdown percentage of the 







Figure 5.37 The splitting of the protein analysis from SA43 aptamer and 1321N1 cell 
line.  
Over a quarter of the biding is with nucleic acid binding proteins (pink sector) along with 
presence of cytoskeletal structure protein, transporters and transfer proteins amongst 
other hits. 
5.4.2 Analysis of pulldown results 
5.4.2.1 Specific proteomic analysis of regions in U87MG cells 
Subsequent pulldown was done with U87MG cells using SA43 and SA44 aptamers and 
sent for mass spectrometry analysis to confirm the targets of pulldown. Following 
method development and previous results, the analysis was limited to visualised protein 
bands of strong visibility and guided by the results of the first mass spectrometry 
analysis. Proteins of significance were found following repeat analysis of the same band 
from different aptamer-pulldowns, and were identified to be ku70 and ku80, as shown 
by the band between 60-80kDa in Figure 5.38. Ku70 and Ku80 and similar sized bands 
were detected on all subsequent gels involving SA43 and SA44 aptamers incubated with 




Figure 5.38 U87MG aptamer pulldown for mass spectrometry 
 Repeat aptamer assisted pulldown with SA43 and U87MG cell line twice showing 
consistent bands between 60 to 80kda. The bands were excised and sent for mass 
spectrometry analysis. 
Further mass spectrometry analysis of the gel bands at 80kDa revealed XRCC5 (X-ray 
cross complementing protein 5), also known as Ku80 to be enriched along with the 
presence of cytokeratin fragments. Gel bands at the region of approximately 60kDa 
came back as XRCC6 (X-ray cross complementing protein 6, also known as Ku70) in both 
repeats of mass spectrometry analysis of pulldown and replication protein A with 
molecular weight of 70kDa.  
5.4.2.2 Analysis of aptamer assisted pulldown in other cell lines  
To further strengthen the robustness of the results and methodology of the technique, 
aptamer assisted pulldown using SA43 and SA44 aptamers was performed on other 
short term cultures derived from patient tissue. Cell lines BTNW 911 and BTNW 914 
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were used along with W859 and W2045 short term cultures, sourced from the University 
of Wolverhampton. The results of the gel electrophoresis separation of proteins eluted 
from the aptamer pull-down are shown below. 
 
 
Figure 5.39 Aptamer assisted pulldown with BTNW short term cultures 
Aptamer-assisted pulldown with SA44 and SA43 aptamer with BTNW 911 (image A) and 
BTNW 914 (image B). Images C and D show the gel blocks excised and sent for mass 
spectrometry analysis. A larger area was excised due to faint bands and possibility of 
crossover while cutting bands. 
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The analysis revealed presence of Ku70 and Ku80 in the gel blocks sent for both tissue 
derived cell lines along with presence of unidentified proteins on the mass spectrometry 
analysis. For the first time, poly ADP-ribose polymerase (PARP) was isolated as a 
significant hit along with ku80 in BTNW 911 and SA43 assisted pulldown. Due to the 
nature of short-term cultures and their growth characteristics, this experiment was 
performed twice and mass spectrometry was performed once. 
 
Figure 5.40 Aptamer assisted pulldown with Wolverhampton cell lines 
Aptamer assisted pulldown with SA43 and SA44 and short term cultures W2045 (A) and 
W859 (B). Both pulldowns showed bands between 60-100kDa.  
Due to the nature of short term cultures and growth curves, this was performed once 
and the proteomic analysis was not performed with SA43 and SA44 but other aptamers 
as seen in the next section with short term cultures W2045 and W859. 
5.4.3 Analysis of aptamer assisted pulldown using novel aptamers 
Novel aptamers with TDM prefix were generated in house by SELEX in a parallel project 
under similar conditions to the SA aptamer but with a different negative selection. The 





Figure 5.41 Aptamer-assisted pulldown using SA and TDM aptamers with U87MG cell 
line.  
Block A to E as labelled were sent for mass spectrometry analysis. Gel bands A and C 
exclusively showed presence of ku80 along with contaminant cytokeratin of human 
origin on mass spectrometry analysis. Gel bands B showed Ku70 exclusively of human 
origin. Gel band D showed maximal presence of Ku70 and an isoform of Ku70. Pie chart 
showing the protein class distribution from SAneg1, block E. DNA helicase Q1 was also 
isolated, which is responsible for DNA repair. Gel block E showed highest signal of 
100kDa coactivator or SND1 (staphylococcal nuclease domain containing protein 1), 
responsible for mRNA function. Vigilin, an RNA binding protein responsible for fat 






Figure 5.42 Aptamer assisted pulldown with W2045 short term culture.  
SA43 and SA44 aptamers along with TDM aptamers were used for the pulldown. Red 
blocks marked as A and B were the gel segments sent for mass spectrometry analysis. 
Gel block A showed presence of vigilin and 100kDa coactivator with highest significant 
matches as seen with U87MG in figure 5.40. Pie chart showing the protein class 
distribution using panther analysis for SAneg1, block A. Other isolated proteins included 
transporter proteins and unnamed proteins of human origin. Gel band B showed 
heterogeneous nuclear ribonucleoprotein K as most significant, which is responsible for 





Figure 5.43 Aptamer assisted pulldown with W859 short term culture.  
SA43 and SA44 aptamers along with TDM aptamers were used for the pulldown. Red 
blocks marked as C, D, E, F and G were the gel blocks sent for mass spectrometry analysis. 
Gel block E showed Ku70 and Ku80 as seen in earlier mass spectrometry analysis along 
with nucleolin, replication protein A and PARP as significant hits. Gel block F and G also 
showed ku70 and ku80 with replication protein A and PARP with less significance. Pie 
chart showing the protein class distribution using panther analysis for SAneg1, block C. 
Gel block C showed vigilin and 100kda coactivator as seen in figure 5.40 and figure 5.41. 
Gel block D again showed heterogeneous nuclear ribonucleoprotein K as most 
significant, similar to figure 5.41 in W2045 cell culture.  
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The TDM aptamers were generated towards U87MG cells and were included in the 
research project to further support and validate the results. The aptamer pulldown 
results from U87MG cell lines using selected TDM aptamers as shown in Figure 5.41 with 
blocks sent (Figure 5.18 without blocks marked of the same gel image) and from 
Wolverhampton cells in Figures 5.42 and 5.43, shows the similar pulldown results. TDM 
aptamers appear to bind to the same targets whereas the SANeg1 does not show 
binding to ku70 and ku80. 
The mass spectrometry analysis of SANeg1 shows that it is consistently pulling a 
different subset of proteins and thus is a good and valid control with three repeats with 
different cell cultures. 
5.5 Discussion 
In chapter 4, we confirmed the binding affinity of the Cy3 tagged aptamers to glioma 
cell lines. Replacing biotin tag on the aptamers and incubation with fixed cells also 
showed good binding results. This reconfirmed the basis of the current chapter, to 
employ the biotin and streptavidin affinity and achieve a pulldown of the target epitope.  
Before attempting pulldown, Optimal protein extraction from cells was required. The 
first step in working towards achieving a pulldown is to have consistent, good quality 
protein or target moiety. If the protein extraction varies, it can affect the development 
of the aptamer pulldown and give false positive results. The first attempts were made 
using fixed cells. The initial intention was to crosslink the reacted aptamer and hence 
reduce the chances of loss of the relevant target downstream from treatment, an 
adaptation directly from ChIP. Pre-reacting and crosslinking did not work due to varying 
degree of cross linking. Once crosslinked, aptamer linked biotin itself became 
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crosslinked and hence unavailable for binding to streptavidin. Biotin and streptavidin 
binding is the basis for DAB staining and ChIP. Reversal of crosslinking required harsh 
treatments and poor quality of protein as seen in the figures 5.7 and 5.8 when compared 
to unfixed cells. Though heat treatment of the reversal of crosslinking did show results 
(figure 5.10), the quality of bands on gel remained poorer than unfixed cells. It also left 
the aptamer in a non-physiological state due to the heat reversal of crosslinking. The 
poor protein content was also evident on Bradford assays and protein samples on gels 
as in figure 5.8 and 5.10. Protein extraction with unfixed cells is widely used for most 
mammalian research and has established protocols.  
RIPA and triton X100 gave the most consistent results of protein extraction with least 
amount of stress to the cells in an unfixed state. RIPA and triton X100 gave comparable 
results of protein extraction with unfixed cells. After further review and analysis triton 
X100 was utilised for protein extraction due to be least interfering with protein assays 
and to keep the targets in its native state (Labeta et al., 1988). RIPA also has a good 
action for releasing greater nuclear content when compared to triton X100. Due to the 
presence of staining in chapter 4 in both cytoplasm and nucleus, it was felt that the likely 
target is expressed both in cytoplasm and nucleus. Though it was also known that the 
aptamer uptake is an active process, the likelihood of the target being cytoplasmic and 
on cell surface was greater. Hence, triton X100 was also chosen due to relative reduced 
nuclear content lysis in triton X100 compare to RIPA. 
The pulldown method was the next step developed and utilised for aptamer assisted 
pulldown of proteins in section 5.3. Native Streptavidin-biotin affinity was adapter from 
ChIP (Aparicio et al., 2004) and utilised for developing the pull-down technique for 
aptamer assisted precipitation. Magnetic beads were first utilised due to assisted 
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sedimentation but due to excessive non-specific pull-down as in figure 5.11, 
streptavidin-agarose beads were utilised for further method development. After 
optimising washing steps, U87MG showed pull-down of specific bands as in figure 5.12 
with SA43 and SA44. The method was repeated thrice to confirm repeatability and to 
eliminate non-specific pulldowns. After establishing the protocol with U87MG cell line, 
it was then applied for 1321N1 and SVGp12 cell lines to confirm the method robustness. 
Consistent repeat pull-down with U87MG, 1321N1 and SVGp12 cell lines confirmed 
optimisation of method and it was further expanded to test on short term cultures. The 
aptamer pulldown on all three cell lines U87MG, 1321N1 and SVGp12, all showed bands 
in similar molecular weight distribution between 100 to 60 kda. This was interesting to 
note as binding had been seen in SVGp12 cell line as well and it was not clear if the 
binding targets were same. 
To further confirm the stability of the method, it was applied to short term cultures with 
exact same steps. Short term cultures BTNW911 and BTNW914 showed pull-down as in 
figure 5.15 and 5.16. Due to the nature of the short term cultures, repeat experiments 
could not be performed and target bands were faint. But the bands were also seen in 
the same distribution as the glioma cells lines, thus increasing the potential of the work. 
Wolverhampton cell lines W2045 and W859 were then used to test the aptamer and 
method and showed consistent pull-down at 60-100kDa (figure 5.17). the pulldown 
bands were verified later in chapter 5.4 with mass spectrometry and the targets 
confirmed to be Ku70 and ku80. 
The aptamers used until now were sequences which had been truncated from Cerchia 
et al. Aptamer pull-down was the performed with novel aptamers and SANeg1 and 
SAneg2 aptamers with the cell lines and short term cultures to expand the results and 
141 
 
confirm the method development. The pull-down with SAneg1 showed bands at 
different molecular weight compared to the rest of the aptamers, SA and TDMs as seen 
in figures 5.18, 5.19 and 5.20. SAneg1 and all the other aptamer pulldown bands were 
then sent for mass spectroscopy to St Andrews university, Dundee for confirmation of 
targets as in section 5.4. 
Aptamer structures were reviewed with Mfold (Zuker, 2003), open software for 
predicted aptamer structures. Aptamers due to being single stranded, bend and fold to 
form different structures and loops. The loops are formed in the aptamer and said to 
influence the binding to targets (Feigon et al., 1996). Hence, if the loops are similar, it is 
possible that the aptamers with two slightly different sequences can still bind to the 
same target. This is evident with the SA44 and SA443 aptamer which have a difference 
of only one nucleotide. The aptamers finally bind in a 3D structure under covalent 
bonding and van der waals forces. Common patterns were found in SA43 and SA44 as 
expected. SA43 aptamer could fold into five different 2D structures (figure 5.22) 
whereas SA44 only had two 2D structures (figure 5.23). The SA44 structures are identical 
to two of the SA43 structures and can explain the similarity in pulldown results. But SA43 
is also the only aptamer which showed pulldown of PARP (section 5.4). It is hence likely 
that one of the other structure binds to PARP and the aptamer is in a state of different 
stoichiometry.  
SANeg1 aptamer showed three different structures and did not show any similar loops 
like SA43 or SA44 aptamer (figure 5.24). SANeg2, TDM2, TDM3 and TDM7 instead 
showed only single predicted 2D structures of the aptamers and showed binding to the 
target. TDM9 and TDM10 aptamers have more than one predicted 2D structure and still 
showed binding to ku70 and ku80.The novel aptamers though do not share any loop 
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patterns but still showed similar pulldown and confirmed later with mass spectrometry. 
Despite having different structures, the targets pulled were similar though the aptamers 
with single predicted 2D structure had most abundant target as ku70 and ku80. 
Mass spectrometry gives a report of target “hits” in the results. Interpretation of the 
data requires caution, as the true target ligands can be masked by other proteins and 
protein complexes that have been pulled with the target. The gel bands and blocks were 
sent for mass spectrometry and showed consistent presence of Ku70 and Ku80 with 
SA43, SA44, SAneg2 and TDM aptamers with all cell lines and short term cultures. The 
only aptamer which showed different bands in the pulldown and consistently, was 
SANeg1. The gel bands for SANeg1 were also sent for mass spectrometry and 
consistently showed pulldown of vigilin and 100kDa coactivator protein, with molecular 
weight of 140kDa and 100kDa, respectively.  Despite the application of the same method 
and against all the cells lines used, SAneg1 pulldown was different every single time. This 
thus confirmed that the aptamer binding is specific in the glioma cell lines and short 
term cultures to the aptamers and novels aptamers except SANeg1. SANeg1 thus was a 
valid control.  
The proteomic analysis also pulled down a lot of other proteins but ku70 and ku80 were 
amongst the highest in terms of presence and consistency. Ku70 and ku80 being DNA 
repair proteins were the most abundant and likely target for the aptamer. Poly ADP 
ribose or PARP was also detected in the pulldown with the SA43 aptamer. When the 
spectrometry analysis of the aptamers was compared against each other only SA43 
appeared to pulldown PARP as well and seen in U87MG, 1321N1 and also BTNW 911 
cell line. PARP are a family of enzymes that have the ability to transfer ADP-ribose to 
target proteins. PARP plays important roles in cellular processes including DNA repair in 
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homologous repair mechanisms (Morales et al., 2014) and likely involved in other cancer 
types (Fulton et al., 2017; Miller et al., 2019; Robson et al., 2019).  
Replication protein A, a 70 kda subunit was also identified in some pulldowns. 
Replication protein A is involved in keeping the single stranded DNA straight and to 
prevent from forming loops and has also been identified as a potential target to 
developing therapies (Zou et al., 2006; Liu and Huang, 2016).  
Multiple other proteins, nucleolin and cytokeratin structures were pulled down with 
SA43 and SA44 aptamers but were not significant due to not being reproducible in other 
pulldowns. TDM2 TDM3 and TDM7 mainly showed pulldown of ku70 and ku80 proteins 
and were more significant in producing consistent, specific pulldown when compared to 
SA43 and SA44. 
Ku70 and Ku80 were the most consistent and abundant proteins detected on mass 
spectrometry with the aptamers except SANeg1. Further research into publications 
showed increased ku70 and ku80 expression in various cancers and the presence in DSB 
repair pathway via NHEJ. Hence, they became the main focus for confirmatory 
experiments.  Confirmation of the results was needed and expanded in chapter 6 with 























6 Verification of aptamer assisted pulldown 
6.1.1 Introduction 
In the previous chapter, optimal protein extraction was developed using triton X100 for 
cell lysis which was then used for aptamer assisted pulldown of epitopes. These pull-
downs were run on 10% SDS PAGE gels, and then sections of gel were excised and sent 
for mass spectroscopy analysis at St Andrews University, Dundee. Initial pull-downs had 
entire columns sent for mass spectrometry. At later stages, consistent bands at 70 – 80 
Kda pointed towards the greater possibility of Ku70 and Ku80 proteins being the primary 
target of the aptamers. 
Ku70 and Ku80 exist as a heterodimer protein in the cell nucleus. This is present during 
Non-homologous end joining (NHEJ) (Moore and Haber, 1996) or cell division. NHEJ is a 
form of DNA repair where homology of the DNA ends is not needed for division and 
repair (Moore and Haber, 1996). The Ku heterodimer is present normally in the cell 
nucleus. There is also supported evidence to suggest that due to over detection, these 
proteins are present in the cytoplasm of the cells and also expressed on the cell surface 
(Prabhakar et al., 1990; Dalziel et al., 1992; Persson et al., 2010). 
Presence of these proteins on the cell surface would support the notion the Ku 
heterodimer as a potential therapeutic target for glioma.  To move forward, it is 
essential to confirm the results of the pulldown and mass spectroscopy. The aim of this 
chapter is to confirm the aptamers targets as Ku70/80 heterodimer in glioma cell lines 
and short-term cultures. 
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6.1.2 Ku70 and Ku80 detection in Commercial cell lines 
Mass spectroscopy analysis supported abundant presence and pulldown of Ku70 and 
Ku80 protein when compared to whole cell lysate. This prompted the first experiment 
to evaluate detection of Ku70 and Ku80 in commercial cell lines. Cell cultures were 
grown to 80% confluence in chamber slides and fixed with 4% PFA. They were then 
permeabilised and subjected to immunostaining with anti Ku70 and Ku80 antibodies. 
Two sets of immunostaining were performed; one set utilising anti Ku70 and Ku80 biotin 
tagged secondary antibody, and the other utilised an Alexa 488 anti Ku70 or Ku80 






Figure 6.1 Ku70 and Ku80 detection in U87MG, 1321N1 and SVGp12 cell lines. 
Ku70 detection is high in U87MG cells compared to 1321N1 and SVGp12 (A, D and G).  
Detection is seen in the nucleus and cytoplasm of all cell lines. Ku 80 detection is higher 
in U87MG and 1321N1 compared to SVGp12 (B, E and H) and is detected in the nucleus 





Figure 6.2 Ku70 and Ku80 detection in U87MG, 1321N1 and SVGp12. 
Intense nuclear Ku70 staining was detected in all cell lines (A, D and G).  U87MG also 
exhibited intense cytoplasmic staining (A).  Cytoplasmic staining was also detected in 
1321N1 and SVGp12 (D and G), although to a lesser extent than U87MG (A). Ku70 
detection was detected in the nucleus and cytoplasm of all cell lines (B, E and H).  C, F 




6.2 Western blot analysis and densitometry 
Antibody staining for Ku70 and Ku80 in glioma cell lines above showed significant 
presence of both proteins in the glioma cell lines. Further confirmation of the abundance 
of the Ku heterodimer was planned by performing western blot analysis and probing for 
the proteins. Densitometry analysis was done to assess the presence of the proteins in 
the pulldown and compared to the control aptamer and no aptamer (ref methods). 
Densitometry was also done from cellular lysate, without aptamer treatment to assess 
for total detection of Ku70 and Ku80 proteins. 
6.3 Ku 70/80 detection in cell lines with aptamer 
Aptamer pulldowns from various cell lines was done. The figures below show the 
percentage of pulldown seen in each of the columns confirming presence of Ku70 and 





Figure 6.3 U87MG cell lysate aptamer assisted precipitation and probing with Ku70 
and Ku80 antibody 
The above figure shows blotting and probing of the aptamer pulldown with Ku70 and 
Ku80 antibody. There appears to be greater presence of Ku70 in the cell lysate as seen in 
the input column. Ku70 and Ku80 detection is seen in all columns except SAneg1 and 
control (no aptamer). This confirms that the pulldown is specific and detection of the 
proteins is present. Figure 6.3 showing densitometry analysis for Ku70 and Ku80 bands 
on U87MG probing. The densitometry analysis was done using Imagej software.  The 
input from the cell lysate is the reference for each graph separately and as one. The pull-
downs show greater detection of Ku70 and Ku80 except SANeg1 aptamer. (Ku70 graph 








Figure 6.4 1321N1 cell lysate aptamer assisted precipitation and probing with Ku70 
and Ku80 antibody 
The above figure shows blotting and probing of the aptamer pulldown with Ku70 and 
Ku80 antibody. There appears to be greater presence of Ku70 in the cell lysate as seen in 
the input column. Ku70 and Ku80 detection is seen in all columns except SAneg1 and 
control (no aptamer). This confirms that the pulldown is specific and detection of the 
proteins is present. Figure showing densitometry analysis for Ku70 and Ku80 bands on 
1321N1 probing. The densitometry analysis was done using Imagej software. The input 
from the cell lysate is the reference for each graph separately and as one. The pull-downs 
show greater detection of Ku70 and Ku80 except SANeg1 aptamer. TDM9 and TDM10 
have the lowest relative detection in 1321N1 compared to input detection. (Ku70 graph 






6.4 Ku 70/80 detection in short term cultures with aptamer  
Aptamer pulldowns from various short term cultures was done. The figures below show 
the percentage of pulldown seen in each of the columns confirming presence of Ku70 
and Ku80. All experiments were performed at the same times and temperature 
conditions. 
 
Figure 6.5 BTNW914 cell lysate aptamer assisted precipitation and probing with Ku70 
and Ku80 antibody 
The above figure shows blotting and probing of the aptamer pulldown with Ku70 and 
Ku80 antibody. There appears to be greater presence of Ku70 in the cell lysate as seen 
in the input column. This is much higher than the cell lines and in a ratio of 80:20. Ku70 
and Ku80 detection is seen in all columns except SAneg1 and control (no aptamer). This 
confirms that the pulldown is specific and detection of the proteins is present. Figure 
showing densitometry analysis for Ku70 and Ku80 bands on BTNW914 probing. The 
densitometry analysis was done using Imagej software. The input from the cell lysate is 
the reference for each graph separately and as one. The pull-downs show greater 
detection of Ku70 and Ku80 except SANeg1 aptamer. TDM2 and TDM3 have the 
highest relative detection in BTNW914 compared to input detection. (Ku70 graph on 





Figure 6.6 W2045 cell lysate aptamer assisted precipitation and probing with Ku70 and 
Ku80 antibody 
The above figure shows blotting and probing of the aptamer pulldown with Ku70 and 
Ku80 antibody. There appears to be near equivalent presence of Ku70 in the cell lysate 
as Ku80, as seen in the input column. This is in variation to both the cell lines and also 
BTNW914. Ku70 and Ku80 detection is seen in all columns except SAneg1 and control (no 
aptamer). This confirms that the pulldown is specific and detection of the proteins is 
present. Figure showing densitometry analysis for Ku70 and Ku80 bands on W2045 
probing. The densitometry analysis was done using Imagej software.  The input from the 
cell lysate is the reference for each graph separately and as one. The pull-downs show 
greater detection of Ku70 and Ku80 except SANeg1 aptamer. The relative detection of 
Ku70 and Ku80 are the highest in W2045 when compared to other cell lysates. (Ku70 








Figure 6.7 Aptamer pulldown followed by Ku70 and Ku80 antibody probing in W859 
short term glioma cultures 
The above figure shows blotting and probing of the aptamer pulldown with Ku70 and 
Ku80 antibody. The input lane shows presence of ku70 and ku80 in the cell lysate. 
Aptamer columns shows bands with Ku70 and Ku80 antibody probing. There appears to 
be greater detection of Ku70 in the aptamer assisted pulldown compared to the input 
column. Ku70 and Ku80 detection is seen in all columns except SAneg1 and control (no 
aptamer). Figure showing densitometry analysis for Ku70 and Ku80 bands on W859 
probing. The densitometry analysis was done using Imagej software. The input from the 
cell lysate is the reference for each graph separately and as one. The pull-downs show 
greater detection of Ku70 and Ku80 except SANeg1 aptamer. TDM9 and TDM10 have 
the lowest relative detection in W859 compared to input detection. W859 also has high 





Figures 6.3, 6.4, 6.5, 6.6 and 6.7 show consistent higher detection of Ku70 and Ku80 in 
the aptamer precipitation using SA43, SA44, TDM2, TDM3, TDM7 and SAneg2 
aptamers. It is also seen in TDM9 and TDM 10 but at a lesser relative quantity. SAneg 1 
does not shows any signal on densitometry analysis his is similar in detection in the 
input as U87MG and 1321N1 cell lines. This confirms that the pulldown is specific and 
pull-down of the proteins is present and specific.  
 
6.5 Ku70/80 detection in cell lysate 
Ku70 and ku80 was detected by mass spectrometry analysis and seen in pulldown with 
all the cell lines used. Due to the normal presence of ku70 and ku80 in cell nuclei, normal 
human astrocytes or NHA were incorporated to compare the presence of ku70 and ku80 
in the NHA against the glial cell lines and short term cultures. Cell lysates of U87MG, 
1321N1, SVGp12 and NHA were prepared as per the protocol for aptamer reaction. 
Aliquots of the lysates were then run on gel for western blotting and probed for Ku70 
and Ku80 antibody to detect presence of the proteins in comparison to each other.  
6.5.1 Densitometry analysis of cell lysate gel 
Cell lysates of U87MG, 1321N1, SVGp12 and NHA as prepared above were run on gel at 
0.3mg aliquots on Bradford assay. These were then compared on gel-doc and analysed 




Figure 6.8 Gel run for cell lysates 1321N1, U87MG, SVGp12 and NHA 
Cell lysates of 1321N1, U87MG, SVGp12 and NHA were run on a gel at 0.3mg/ml to look 
for protein band detection. The cell lysates show similar distribution of gel bands 
compared to each other as seen in A. Figure B shows the auto analysis using imagelab 




Figure 6.9  Percentage breakdown of bands on densitometry analysis in the four cell 
lysates from figure 6.8  
The y axis is percentage of total protein content in the lane, relative to summation of 
measured density of all bands in the lane for specific cell lysate and x axis are the 
individual protein bands numbered 1-21 in each lane seen in figure 6.8. The green loop 
is around band 7 as seen in the figure 6.8 (B) of the gel and conforms to molecular 
weight around 60-80 KDa. Each bar corresponds to a different cell line and different 
lane within the gel. Densitometry analysis of the gel from figure 6.8 shows increased 
band detection in 1321, U87MG and SVGp12 at 60-80kda when compared to NHA. The 
higher percentage in 1321N1 and U87MG could be due to higher Ku protein content in 
the cells. This is less in the NHA column at band 7. Higher detection of smaller, 
molecular weight contents are seen further down the graph between 17-19 bands 
which are in close proximity in the gel. This also supports that despite other proteins 
and compounds in the cell, the aptamers do specifically pull-down Ku70 and Ku80. 
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Densitometry analysis showed increased detection around band 7 from top which is 
similar in columns of U87MG and 1321N1 and around 60-90kDa. At the same kDa, the 
bands in the SVGp12 and NHA are smaller, more so in NHA. This is also seen in the 
aptamer pulldown probing with Ku70 and Ku80. 
 
Figure 6.10  Ku70 and Ku80 antibody probing on the whole cell lysates from the image 
6.8.  
Whole cell lysate was probed for Ku70 and Ku80 relative expression in 1321N1, U87MG, 
SVGp12 and NHA cell lines. The top band in each column is for Ku80, the second from top 
is Ku70. The third lowest band is β actin to confirm protein presence. There is highest 
protein content in the NHA column but the lowest detection of Ku70 and Ku80 relative 




6.6 Knockdown results of Ku70 and Ku80 
To determine whether Ku70/80 proteins were the targets for both SA43 and SA44 
aptamers, Ku70 and Ku80 proteins were knocked down by siRNA in U87MG cells, either 
individually or simultaneously, and biotin tagged SA43 and SA44 aptamers were 
incubated with the cells.  The results show that compared to the wild type (no knock 
down) U87MG cells, there was reduced binding of both SA43 and SA44 aptamers in Ku70 
knockdown U87MG cells, Ku80 U87MG cells, and no binding in Ku70/80 knockdown 





Figure 6.11 Aptamer staining after knock down by siRNA of Ku70 and Ku80 in U87MG 
cells. 
In figure, A, E and I are aptamer staining with standard U87MG cells as positive control. 
M, N, O and P are negative controls with no aptamer addition in any of the cells with 
and without knockdown of Ku 70 or Ku80. Figure B, F and J have the effect of Ku70 
knockdown on U87MG cells and then incubation with aptamers. There is reduced 
binding seen around the nucleus with SA43 and SA44 aptamer incubation in B and F 
respectively but binding seen in the cytoplasm. SAneg1 does how some nuclear binding 
but all three, B,f and J are reduced compared to the wildtype. In C, G and K, Ku80 has 
been knocked down and in comparison, there appears to be even lesser binding seen 
with all three aptamers, SA43, SA44 and SAneg1. In d, H and L, both Ku70 and Ku80 
knockdown has been performed. There is again minimal cytoplasmic binding seen with 
SA43 aptamer and very little with SA44 and SAneg1. Cell morphology appears to be 




In order to verify the aptamer target in glioma cell lines, aptamer assisted pulldown was 
performed in chapter 5. This showed protein bands between 60-100 KDa on the protein 
ladder.  Excision of these bands followed by mass spectrometry analysis suggested the 
SA43 and SA44 aptamer were as Ku70 and Ku80 proteins. The aptamer assisted 
pulldown protocol was then applied to patient derived short term cultures, and mass 
spectrometry analysis revealed the target protein for SA43 and SA44 aptamer was also 
Ku70 and Ku80.  Mass spectrometry can generate a number of target “hits” in the data 
report, therefore interpretation of the data requires caution, as the true target ligand 
might be masked by high levels of e.g. chaperone proteins or protein complexes that 
have been pulled down with the target.  The aim of chapter six was to confirm the target 
ligand for SA43 and SA44 aptamers. 
Publications have highlighted the increased detection of Ku70 and Ku80 in multiple 
tumours such as breast, colorectal, prostate and bladder (Prabhakar et al., 1990; Dalziel 
et al., 1992; Pucci et al., 2001; Mazzarelli et al., 2005; Chang et al., 2006; Alshareeda et 
al., 2013). PARP or Poly ADP ribose polymerase has recently been discussed in cancer 
research. It is also responsible for cell repair and is overexpressed in cancer cells. It is 
being researched for targeted therapy (Morales et al., 2014). PARP in our mass 
spectrometry analysis appears to bind in pull-downs to SA43 aptamer along with Ku70 
and Ku80. This is exclusively seen with SA43 aptamer in U87MG and short term cultures. 
This is likely due to the multiple structures predicted for the aptamer and could well be 
used for targeting PARP as well. Olaparib is a PARP inhibitor with USFDA approval for 
use towards BRCA mutated ovarian cancer (Mirza et al., 2018). PARP plays an important 
role in DNA repair (Morales et al., 2014) and is also involved in other cancers like breast, 
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peritoneal and also glioma (Fulton et al., 2017; Miller et al., 2019; Robson et al., 2019). 
PARADIGM or Olapraib and radiotherapy for people with glioblastoma trial has looked 
at the use of olaparib in conjunction with temozolamide and radiotherapy. The trial is 
now evolved into PARADIGM 2 or looking at olaparib with radiotherapy alone and 
olaparib with radiotherapy and temozolamide combined. Dose changes in olaparib has 
been done to accommodate the hematological toxicity when combined with 
temozolamide. Patients are segregated according to their MGMT status and dose 
escalation in unmethylated patients can be done in the absence of temozolamide and 
minimal risk of hematological toxicity. OPARATIC trial (Olaparib with temozolamide for 
glioblastoma that has come back) has also looked at recurrent glioma (Halford et al., 
2017). 
Ku70 and Ku80 are DNA repair proteins involved in NHEJ for DSB repair and are over-
expressed in a lot of cancers. Previous studies have shown the heterodimer to be 
present normally in cell nucleus, facilitating double stranded break (DSB) repair (Davis 
and Chen, 2013) via NHEJ and increased detection occurs after cell damage for DNA 
repair. DSB is a break in the DNA which results in both strands to be broken and repair 
is crucial to prevent aberrant repair, apoptosis or cancer genesis (Davis and Chen, 2013). 
DSB and NHEJ is upregulated in GBM (Annovazzi et al., 2015). Looking at the Kyoto 
encyclopaedia of genes and genomes or KEGG, NHEJ is seen with presence of Ku70 and 
Ku80 in glioma repair (KEGG). There is reported over detection in glioma but follow up 
studies have been scarce.  In order to verify Ku70/80 as the target ligand for SA43 and 
SA44 aptamer, it was first necessary to confirm detection of Ku70 and Ku80 in the cells.  
Immunocytochemistry confirmed the nuclear and cytoplasmic detection of Ku70 and 
Ku80 in glioma cell lines and astrocyte control cell line.  As expected, detection was high 
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in the glioma cell lines with detectable, but reduced detection, in the control astrocyte 
cell line.   
The next step was to perform Western blot analysis on the protein extracts and 
precipitates. Cells were lysed and pulldown performed using aptamers SA43 and SA44. 
Novel TDM aptamers generated at UCLan were also used in the experiments, which 
were generated towards U87MG cells (Manangazira, 2013). 10 different aptamer 
sequences were generated after SELEX at Uclan against U87MG cell lines which were 
different to previously published aptamer sequences. Under graduate projects used the 
novel aptamers against glial cell lines and five sequences were shown to stain positively 
towards U87MG cell lines. 
The five novel aptamers from the SELEX were utilised for pulldown with the same 
protocol. These aptamers were also used towards short term sequences to expand the 
cohort of samples and hence, increased the statistical significance of the results.  Novel 
aptamer used in the study were generated using SELEX and developed with positive 
selection towards U87MG cell line. The  fact that the novel aptamers also pulldown the 
same targets  supports the validity of the pulldown technique. This also indicates that 









7 Discussion and future direction 
7.1 Current situation and basis of research 
The aim of the research project was to identify the targets of aptamers in glioma. The 
current treatment management for glioma harbours on surgery followed by 
concomitant chemo and radiotherapy as per the Stupp protocol (Stupp et al., 2005). The 
heterogeneity of glioma (Kleihues et al., 2002) and the lack of clear tumour margins 
(Neira et al., 2017)  makes curing glioma a big challenge. This is seen in the slow 
improvement in the meaningful survival of GBM patients over the last 50 years 
(McKinney, 2004; Krex et al., 2007). Poor response to chemotherapy agents when 
compared to other tumours, is majorly due to the poor penetration of the BBB (Deeken 
and Löscher, 2007). Small sized molecules can penetrate the BBB (Geldenhuys et al., 
2015) and are usually lipid molecules (Banks, 2009). Aptamers, being only single 
stranded DNA or RNA and non-immunogenic, could cross the BBB. The usual molecular 
size of substances crossing the BBB are between 400-600Da but molecules up to 78kDa 
in the form of cytokine induced neutrophil chemoattractant-1 are known to pass 
through transmembrane diffusion (Banks, 2010). 
Published aptamer sequences by Cerchia et al, (2009) specific to glioma, were selected. 
These sequences were truncated to make them more specific and shorter to assess for 
better targeting (Macdonald et al., 2016). To confirm that the aptamers are specific to 
glioma, staining with fluorescent tagged aptamers was performed (Chapter 3). Firstly, 
confocal imaging with live aptamer incubation, followed by biotinylated aptamer was 
performed on fixed cells. The biotinylated aptamers were used to enable pulldown of 
target epitope attached to the aptamer using streptavidin affinity to biotin. A parallel 
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project (Aptekar et al., 2015) looked at confirming live aptamer uptake using Cy3 tagged 
aptamer and performing FACS analysis (Aptekar et al., 2015). This confirmed the findings 
seen in the confocal imaging of aptamer uptake and internalisation of the aptamer. 
According to the parallel study, the internalisation of the aptamer was an active process 
as no uptake was seen at 4⁰C. This would imply that a surface ‘target’ is likely to exist 
which helps the aptamer to bind and internalise. There was also no change seen in 
aptamer uptake before and after trypsinisation, thus likely preserving the surface 
‘target’ despite trypsinisation. It is also likely that the aptamers are being internalised 
by a ‘pathway’ and could be one of the already known pathways (EGFR pathway) 
identified to be dysregulated in cancer genomics studies (Creixell et al., 2015).  
The technique for aptamer assisted pulldown of targets was refined and consistent 
results were achieved with clear protein separation bands seen by gel electrophoresis. 
These proteins were then cut from gels and sent for mass spectrometry analysis, initially 
as whole columns (chapter 5). Mass spectrometry analysis of the whole column 
confirmed repeatable identification of Ku proteins (chapter 5). Mass spectrometry thus 
showed identification of Ku proteins in glioma cells and an over detection intracellularly, 
compared to non-cancerous SVGp12 cells, as widely seen in this thesis in microscopy 
experiments and confirmed with pulldown techniques.  
If Ku70 and Ku80 are expressed on the surface of U87MG cells then it is likely that the 
novel aptamers generated using SELEX at UcLan are also selectively binding to the Ku 
proteins as these aptamers were generated under similar physiological conditions to the 
Cerchia aptamers (GL43, -44 and -56) (Manangazira, 2013). The technique used for 
generating the novel aptamers, used U87MG cells for positive selection and introduced 
a negative selection against SVGp12 cells (which was not done by Cerchia et al. (2009). 
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Two random aptamers, SAneg1 and SAneg2 were also generated as an isoform of the 
specific aptamers to create control aptamers. These acted as positive and negative 
controls as seen in the immunostaining experiments as determined in Chapter 4.  If the 
aptamers were specific to Ku proteins as seen largely in the results, they will enable 
distinguishing cancerous cells from non-cancerous and could enable targeted therapy 
(Fischer et al., 2001). Other cancers are known to over-express Ku proteins such as 
colorectal (Beggs et al., 2012), cervical (Beskow et al., 2009),  leukaemia (Pei et al., 2013), 
breast (Alshareeda et al., 2013), prostate (Al-Ubaidi et al., 2013) and bladder cancer 
(Stronati et al., 2001) amongst other cancer tissues (Pucci et al., 2001). The over 
detection of Ku proteins in these cancers could also be targeted (Pucci et al., 2001).  
7.2 Aptamer assisted pulldown and applications 
For the purpose of identification of targets, a novel technique was developed. Aptamer 
assisted pulldown was designed using known techniques of protein extraction and 
modifying ChIP technology (Aparicio et al., 2004; Xu et al., 2010; Ye et al., 2012). ChIP 
techniques showed a way forward on how to enable pulldown using biotin-streptavidin 
affinity (Weber et al., 1989). Streptavidin is a protein purified from Streptomyces 
avidinii, a bacterium (Weber et al., 1989). Streptavidin and biotin (Vitamin B7 or C₁₀ H₁₆ 
O₃ N₂ S) have a very high affinity with a dissociation constant of 10‾¹⁴ mol/l and is the 
strongest non-covalent interaction in nature (Chivers et al., 2011). The bond is also 
extremely resistant to organic solvents and extremes of temperature and pH. The bond 
can break without denaturing streptavidin by heating to 70⁰C in water (Holmberg et al., 
2005). The final protocol was developed for the aptamer pulldown and can theoretically 
be applied to other cell extractions. The two factors which can affect pulldown with cells 
lines is the location of the target epitope and interference with triton X100 (Pchelintsev 
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et al., 2016). The protocol uses cell lysis with triton X100, a non-denaturing agent at very 
low concentration. This was modified from earlier usage to preserve protein function 
and specificity to the aptamer by preserving the protein target in its native form. Triton 
X100 at this concentration does not interfere with proteomic assessment. If the target 
epitope is primarily located on the cell surface, sub-fractionation or differential lysis 
could be performed and aptamer incubated with separate fractions.  
7.3 Confirmation of targets Ku70 and Ku80 
Ku70 and Ku80 exist as a heterodimer in the DNA repair pathway for NHEJ repair 
(Mazzarelli et al., 2005; Alshareeda et al., 2013). We know from various publications of 
DNA repair proteins being overexpressed in various cancers (Moll et al., 1999; Fischer et 
al., 2001; Pucci et al., 2001; Bouchaert et al., 2012). Ku70 and Ku80 has also been shown 
to be present on the surface of cells (Prabhakar et al., 1990). The explanation for over 
detection is the attempt of the cell to repair itself. Similarly, the presence of Ku proteins 
in the cytoplasm and surface is due to diffusion and abundance of the protein. Mass 
spectroscopic analysis of the pulldown from the commercial cell lines and short term 
cultures pointed to over detection of Ku repair proteins which were being targeted by 
the aptamer (chapter 5). To confirm the results, we first looked at presence of Ku protein 
in normal cells as published in literature. Ku protein, though produced in the nucleus for 
Double stranded break or DSB repair through NHEJ, is present in the cytoplasm of 
healthy cells compared to senescent cells (Seluanov et al., 2007). This was seen with 
reduced detection seen in DAB staining of SVGp12 and very minimal in NHA cells. It was 
also confirmed with cell lysate detection seen in chapter 6 of NHA. We already know its 
over-detection in various cancerous cells (Pucci et al., 2001).   
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We then confirmed our mass spectroscopy results by probing for Ku proteins. This was 
done using immunocytochemistry using anti Ku antibodies. This showed consistent 
results of presence of Ku70, much more than Ku80 in the various glial cell lines (chapter 
6).  
The next step was to perform the aptamer pulldown and confirmation using Western 
blot analysis. This was also to show the total detection of Ku proteins in the cell lines 
and specificity of the aptamers when compared to the whole cell lysate. The selectivity 
of the aptamers was further highlighted by the fact the control aptamer did not pull-
down Ku protein and no binding detected on the Western blots.  
Further confirmation was done with knockdown of Ku proteins in cells. To confirm the 
targeting of Ku heterodimer and variation in binding, mRNA knockdown was performed 
in U87MG cells and short term cultures (Gold et al., 2012). After the knockdown, clear 
differentiation in the staining was seen with lesser nuclear staining compared to 
cytoplasmic in U87MG. This serves as a clear example and is likely due to the abundance 
of Ku protein in the cytoplasm, but the primary effect of the knockdown is seen in the 
nuclear region and hence reduced staining. 
7.4 Ku70 and Ku80 in cell lines and short-term cultures 
The commercial lines used in the project mainly harboured on U87MG cells, which 
originated from a 44yr old female patient in Uppsala, Sweden (Allen et al., 2016). The 
cell line, in a recent publication has been shown to be different from the original U87MG 
cell line and also has a Y chromosome and likely contaminated over the course of the 
years, although it is still confirmed as a glioma cell line. There is no mention in literature 
of proteomic detection of Ku in U87MG or the likely alterations done to create the cell 
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line (Wang et al., 2016). EGFRvIII has been widely reported in U87MG and GBM but was 
not pulled down by the aptamers. DNA repair mechanisms in GBM by Erasimus et al 
(Erasimus et al., 2016) found presence of Ku70/80 along with XRCC1 and XRCC4 and 
PARP1 presence in repair mechanisms in glioma. This conforms with our results, 
especially with SA43 and TDM aptamers for PARP1 and Ku together (Chapter 5).  
We then looked at 1321N1 cell line, a human astrocytoma cell line isolated in 1972 
(England, 2016). It is a sub clone of the cell line 1181N1 which in turn was isolated from 
the parent line U-118 MG. There are no publications present on the actual cloning of the 
cell line and its exact origin. There is no reference to DNA repair protein detection in 
publications with regards to 1321N1 cell line or of Ku or XRCC. 
When we looked at SVGp12, the cell line originated by transfecting plasmids of JC virus 
into foetal brain cells (Wroblewska et al., 1980). Studies into JC virus and polyoma virus 
shows over detection of Ku proteins in infected cells. It also points to dispersion of Ku 
from its nuclear position to cytoplasmic displacement seen in the infected cells (Reston, 
1987). This supports the fact that we found detection Ku protein in SVGp12 cell line and 
aptamer binding in the cytoplasmic region of SVGp12. SVGp12 cell line might not have 
been the best control cell line in hindsight but did lead to explain why we were seeing 
staining in the initial stages of the project. This was especially so since SVGp12 cells were 
used as a negative SELEX round in the production of TDM aptamers. Studies have 
pointed to over detection on Ku proteins on cell surface (Prabhakar et al., 1990) and also 
increased surface detection in hypoxic conditions (Muller et al., 2005). There is also a 
thought that the protein is not primarily a nuclear in location but secreted by plasma 
membrane transporter (Nickel, 2003; Muller et al., 2005). There is also evidence to 
suggest that Ku is involved in pro-survival and pro-invasive processes (Nagase and 
171 
 
Woessner, 1999; Monferran et al., 2004a; Monferran et al., 2004b; Muller et al., 2005). 
It is also possible that the binding is to an isoform of Ku which is over-expressed in 
cancerous cells. It can also be postulated that Ku detection on surface of SVGp12 is not 
present or much reduced compared to other glioma cell lines and has thus served to be 
a viable negative selection in SELEX. 
7.5 Potential future experiments for clinical application  
A move for a quicker diagnosis in cancer is needed to enable earlier diagnosis and 
treatment. The final aim being application of aptamers for glioma therapy and diagnosis. 
For this purpose, greater efforts are being directed towards diagnosis from blood and 
blood markers. Spectroscopy along with microfluidics with biosensors are being 
employed and this is exactly where aptamers can come into play (Liu et al., 2013). 
Due to the over detection of Ku proteins seen in glioma, there is a chance of spillage of 
this into the blood stream. In glioma, the blood brain barrier is disrupted and hence 
theoretically, it is possible for detection of biomarkers in blood. An experiment to 
analyse the same can be done by taking blood samples from healthy patients and those 
having confirmed diagnosis of glioma, before and after surgery. The 
blood/serum/plasma can then be blotted on blotting paper and probed with Ku70/ Ku80 
antibodies for Ku proteins. At the same time, aptamer probing can also be done on a 
parallel dot blot. As a further confirmation, tumour sample from the patient can be lysed 
and assessed for Ku protein over detection. This will give a result in three forms and can 
be applied for future research and clinical applications. This though is not specific to 
glioma and is likely to pick other cancers as well. 
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Recent publications in spectrometry have given strong results to suggest diagnosis with 
serum spectra of up to 90% specificity for glioma (Hands et al., 2016). This is though 
performed without knowing the elements resulting in this spectral change. The results 
of this technology can be more robust with concomitant analysis of the serum and could 
likely be Ku proteins. 
7.6 AP with patient tissue 
Current research has been done with commercial cell lines and short term cultures 
derived from patient tissue. Both these have cell cultures are in a way not a true 
representation of the patient glioma tissue. Glioma’s being heterogeneous in nature are 
made up of various heteromorphic cells and express various proteins (Jung et al., 2011). 
Not much has been mentioned or discussed about the over detection of Ku proteins in 
literature. It is possible that other cancerous cells which are more proliferative in the 
living tissue than in the cultured confines of the lab are present. With this situation 
hence, performing aptamer assisted precipitation from patient tissue would be an ideal 
further research direction. Aptamer probing on tissue sections has already been 
performed in the parallel study by Aptekar et al (Aptekar et al., 2015). This shows the 
presence of certain proteins being targeted by the aptamer and can be used for tissue 
diagnosis. These targets as confirmed by the current research project shows them as 
Ku70 and Ku80. Another precursor could be SELEX with fresh patient tissue. It has 
already been shown that specific aptamers can be generated by single round of SELEX 
with tissue section. This could be utilised towards fresh tissue and will likely provide 




7.7 Crossing the blood brain barrier 
Aptamers are single stranded DNA and RNA oligonucleotides. Human nucleotides are 
0.6nm in length and average 50 nucleotides in length, the whole length of the aptamer 
is approximately 30nm, not taking into account the folding and binding of the aptamer. 
This equates to roughly 15,382Da. The tight junctions of the BBB allow only molecules 
smaller than 500Da weight by passive diffusion (Banks, 2009). Considering this, it is 
unlikely the aptamers are able to passively diffuse through the BBB.  In order to generate 
aptamers which are able to pass the BBB, either by active transport or facilitated 
diffusion or other mechanisms, studies have applied in vitro SELEX to identify aptamers 
that cross the BBB (Kumar, 2015). A parallel study/PhD has evaluated SA43 and found 
to cross a valid human BBB model (Kumar, 2015). Ongoing animal studies have also 
shown the aptamer being localised to the tumour though extracranially at present. It 
supports the likelihood of the aptamer being administered systemically and being able 
to target the tumour. 
7.8 Clinical application of results 
Aptamers have been hailed as replacement for antibodies (Bunka and Stockley, 2006). 
They are non-immunogenic, small, do not need to be kept at cold temperature when 
not suspended and can be emailed as a sequence for local production. Multiple 
publications have cited the possibility of aptamers replacing roles of antibodies in 
diagnosis, treatment and development of new treatment modalities (Brody and Gold, 
2000; Blank and Blind, 2005; Bunka and Stockley, 2006; Berezovski et al., 2008; Bouchard 
et al., 2010; Bunka et al., 2010).  
The current aptamer research into SA43 can be utilised towards diagnosis for glioma as 
already shown by Aptekar et al. Clinical application in patient treatment can be done by 
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using the aptamer conjugated with a fluorescent dye or a near infra-red dye to enable 
surgical excision. Aptamer conjugated with chemotherapy can be used as a targeted 
chemotherapy with less toxicity to the patient and greater compliance. Whether the 
targeting is via systemic administration or by direct infusion techniques/ convection 
(Debinski and Tatter, 2009, 2010; Chapdelaine et al., 2015).  
Another use can be towards use as a screening tool (Bunka et al., 2010). Since ku is over 
expressed and can be detected in blood stream, it can be used as a screening tool for a 
population. Though not as specific as expected at the beginning of the project, it could 
serve as a generic test for cancer screening after further research.  
Tumour diagnosis is labour intensive and can take weeks since the first concern due to 
a neurological sign or decline. Current two-month cancer pathways for delivering cancer 
treatment in the NHS have been under stress and not being met in certain locations. 
Quicker screening and diagnosis of glioma can certainly affect survival rates and a drive 
towards achieving this goal is ongoing. Blood testing using spectrometry has shown the 
proof of concept. It is likely that Ku is over expressed in patient serum and could also be 
used for early diagnosis.  
7.9 Recurrent tumour SELEX, AP and probing with aptamer  
Recurrent glioma is more difficult to treat. It is resistant to standard chemotherapy and 
usually second line of treatment with PCV and other anti-cancer drugs are used. These 
have greater side effects and tumour response is very variable. AP with recurrent 
tumour could enable targeting and create patient specific treatment. Automated SELEX 
from patient tissue at recurrence and generating new novel aptamers can be used for 
targeting, either via tissue directly or primary tumour cell cultures from patient. It can 
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also result in greater understanding of recurrent tumour pathology. By performing AP 
for target protein, the process can give an indication on the change in tumour detection 
or repair mechanism away from NHEJ.  
7.10 Summary 
In Summary, the aim to develop a novel method for performing pulldown using 
aptamers was achieved. The published glioma specific aptamers were tested against cell 
lines and short term cultures and the novel protocol was used with various aptamers 
including novel aptamers generated using SELEX. Data analysis showed and confirmed 
the target to be DNA repair proteins ku70 and ku80. PARP was also found in certain 
pulldown with SA43 aptamer only. The protocol can be used for developing targeted 
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